

**UNITED STATES BANKRUPTCY COURT  
DISTRICT OF NEW JERSEY**

**WOLLMUTH MAHER & DEUTSCH LLP**

Paul R. DeFilippo, Esq.  
500 Fifth Avenue  
New York, New York 10110  
Telephone: (212) 382-3300  
Facsimile: (212) 382-0050  
pdefilippo@wmd-law.com

**JONES DAY**

Gregory M. Gordon, Esq.  
Brad B. Erens, Esq.  
Dan B. Prieto, Esq.  
Amanda Rush, Esq.  
2727 N. Harwood Street  
Dallas, Texas 75201  
Telephone: (214) 220-3939  
Facsimile: (214) 969-5100  
gmgordon@jonesday.com  
bberens@jonesday.com  
dbprieto@jonesday.com  
asrush@jonesday.com  
(Admitted *pro hac vice*)

*PROPOSED ATTORNEYS FOR DEBTOR*

In re:

LTL MANAGEMENT LLC,<sup>1</sup>

Debtor.

Chapter 11

Case No.: 23-12825 (MBK)

Judge: Michael B. Kaplan

---

<sup>1</sup> The last four digits of the Debtor's taxpayer identification number are 6622. The Debtor's address is 501 George Street, New Brunswick, New Jersey 08933.

**DEBTOR'S EXHIBIT LIST FOR HEARING ON THE MOTIONS TO DISMISS DEBTOR'S BANKRUPTCY CASE**

The Debtor hereby files its Exhibit List for the hearing beginning on Tuesday, June 27, 2023 at 9:00 a.m. Eastern Time.

The Debtor reserves all rights to amend this hearing exhibit list. The Debtor reserves the right to identify and admit these or additional exhibits in rebuttal as necessary and appropriate. The Debtor reserves the right to use or admit exhibits identified by any other Party and the right to use or admit any exhibit used at a deposition in this case. The Debtor also may use demonstratives during its hearing presentation. The Debtor's listing of an exhibit does not waive the Debtor's confidentiality designation for any exhibit previously so marked.

**Exhibit List**

Ex.	Description	Beg. Bates No.	Confidential Designation
1.	John Kim Direct Testimony Declaration and Exhibits		
2.	Richard Dickinson Direct Testimony Declaration and Exhibits		
3.	Robert Wuesthoff Direct Testimony Declaration and Exhibits		
4.	Adam Lisman Direct Testimony Declaration and Exhibits		Confidential
5.	Jim Murdica Direct Testimony Declaration and Exhibits		
6.	Mikal Watts Direct Testimony Declaration and Exhibits		
7.	James Onder Direct Testimony Declaration and Exhibits		
8.	Kim Declaration Exhibit A – PSA - Robinson	LTLMGMT-00000914	Confidential
9.	Kim Declaration Exhibit B – PSA – Seeger Weiss	LTLMGMT-00001531	Confidential
10.	Kim Declaration Exhibit C – PSA – Onder	LTLMGMT-00002785	Confidential
11.	Kim Declaration Exhibit D – PSA - Johnson	LTLMGMT-00003371	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
12.	Kim Declaration Exhibit E – PSA – Ferrer	LTLMGMT-00003444	Confidential
13.	Kim Declaration Exhibit F – PSA – Liakos	LTLMGMT-00003462	Confidential
14.	Kim Declaration Exhibit G – PSA – Linville	LTLMGMT-00003480	Confidential
15.	Kim Declaration Exhibit H – PSA – Nachawati	LTLMGMT-00003498	Confidential
16.	Kim Declaration Exhibit I – PSA – McDonald Worley	LTLMGMT-00003647	Confidential
17.	Kim Declaration Exhibit J – PSA – Pulaski	LTLMGMT-00003685	Confidential
18.	Kim Declaration Exhibit K – PSA – Slater	LTLMGMT-00003882	Confidential
19.	Kim Declaration Exhibit L – PSA – Rueb Stoller	LTLMGMT-00003921	Confidential
20.	Kim Declaration Exhibit M – PSA – Trammell	LTLMGMT-00003959	Confidential
21.	Kim Declaration Exhibit N – PSA – Wisner Baum	LTLMGMT-00004005	Confidential
22.	Kim Declaration Exhibit O – PSA – Watts Guerra	LTLMGMT-00004025	Confidential
23.	Kim Declaration Exhibit P – PSA – Andrews & Thornton	LTLMGMT-00017096	Confidential
24.	Kim Declaration Exhibit Q – PSA – Bisnar Chase	LTLMGMT-00017110	Confidential
25.	Kim Declaration Exhibit R – PSA – De La Rosa	LTLMGMT-00017124	Confidential
26.	Kim Declaration Exhibit S – PSA – Heninger	LTLMGMT-00017138	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
27.	Kim Declaration Exhibit T – PSA - Paul	LTLMGMT-00017152	Confidential
28.	Kim Declaration Exhibit U – PSA – Singleton	LTLMGMT-00017166	Confidential
29.	Kim Declaration Exhibit V – PSA – Andres Pereira	LTLMGMT-00004956	Confidential
30.	Kim Declaration Exhibit W – 2-23-23 Board Minutes		Confidential
31.	Kim Declaration Exhibit X – 3-16-23 Board Minutes		
32.	Kim Declaration Exhibit Y – 3-28-23 Board Minutes		
33.	Kim Declaration Exhibit Z – 4-2-23 Board Minutes		
34.	Kim Declaration Exhibit AA – 3-28-23 Board Presentation		
35.	Kim Declaration Exhibit AB – 4-2-23 Board Presentation		
36.	Kim Declaration Exhibit AC – Termination & Substitution Agreement		
37.	Kim Declaration Exhibit AD – 2023 Funding Agreement		
38.	Kim Declaration Exhibit AE – J&J Support Agreement		
39.	Wuesthoff Declaration Exhibit A – 2-23-23 Board Minutes		Confidential
40.	Wuesthoff Declaration Exhibit B – 3-16-23 Board Minutes		
41.	Wuesthoff Declaration Exhibit C - 3-28-23 Board Minutes		
42.	Wuesthoff Declaration Exhibit D – 4-2-23 Board Minutes		
43.	Wuesthoff Declaration Exhibit E – 3-28-23 Board Presentation		Confidential
44.	Wuesthoff Declaration Exhibit F - 4-2-23 Board Presentation		
45.	Wuesthoff Declaration Exhibit G – Termination & Substitution Agreement		
46.	Wuesthoff Declaration Exhibit H – 2023 Funding Agreement		
47.	Wuesthoff Declaration Exhibit I – J&J Support Agreement		
48.	Lisman Declaration Exhibit A – Estimated Discounted Cashflow	LTL 0029874	
49.	Lisman Declaration Exhibit B – 2023-04-02 J&J 10-Q		
50.	Lisman Declaration Exhibit C – Bell Report Exhibit C		
51.	Lisman Declaration Exhibit D	LTLMGMT-00014004	Confidential
52.	Lisman Declaration Exhibit E – KPMG Fair Market Value of Certain Legal Entities of GH Biotech Holdings Limited	LTLMGMT-00014005	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
53.	Lisman Declaration Exhibit F	LTLMGMT-00013257	Confidential
54.	Lisman Declaration Exhibit G	LTLMGMT-00013209	Confidential
55.	Lisman Declaration Exhibit H -	LTLMGMT-00013463	Confidential
56.	Lisman Declaration Exhibit I	LTLMGMT-00017069	Confidential
57.	Lisman Declaration Exhibit J – J&J March 21, 2019 Alios 8-K		
58.	Lisman Declaration Exhibit K – J&J Vision Statement on Sightbox		
59.	Lisman Declaration Exhibit L – 2022-01-28 Form 8-K		
60.	Lisman Declaration Exhibit M – J&J Completes Acquisition of Abiomed		
61.	Lisman Declaration Exhibit N – 2023-02-16 – Form 10-K		
62.	Murdica Declaration Exhibit 1 – Email from Molton to Gordon and Lauria		
63.	Declaration of John K. Kim in Support of First Day Pleadings, Case No. 23-12825 (“Kim Decl.”), including all exhibits thereto:	LTLMGMT-00000020	
	Annex A to Kim Decl., 1979 Agreement		
	Annex B to Kim Decl., Debtor’s Corporate Structure Chart		
	Annex C to Kim Decl., Form Plan Support Agreement		
	Annex D to Kim Decl., Termination and Substitution Agreement		
	Annex E to Kim Decl., 2023 Funding Agreement		
	Annex F to Kim Decl., J&J Support Agreement		
	Annex G to Kim Decl., March 6, 2023 Letter from Trailblazers		
	Annex H to Kim Decl., March 21, 2023 Letter from Trailblazers’ Counsel		
	Annex I to Kim Decl., Plaintiff’s Response to Defendants’ Opposition to Trailblazer Studios’ Request to Record Trial Proceedings		
64.	Expert Report of Charles H Mullin, PhD and reliance materials – June 7, 2023		Confidential
65.	Rebuttal Expert Report of Charles H. Mullin, PhD and reliance materials – June 14, 2023		Confidential
66.	Expert Report of Gregory K. Bell, Ph.D. and reliance materials – June 7, 2023		Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
67.	Supplemental Expert Report of Gregory K. Bell, Ph.D. and reliance materials – June 20, 2023		Confidential
68.	Expert Report of Sheila L. Birnbaum and reliance materials – June 14, 2023		Confidential
69.	Exhibit C to the Expert Report of Gregory K. Bell, Ph.D. – June 7, 2023		Confidential
70.	Mullin Reliance Materials - LTLMGMT-00015251		Confidential
71.	Mullin Reliance Materials - LTLMGMT-00015252		Confidential
72.	Mullin Reliance Materials - LTLMGMT-00015253		Confidential
73.	Mullin Reliance Materials - LTLMGMT-00015254		Confidential
74.	Mullin Reliance Materials - LTLMGMT-00015345		Confidential
75.	Mullin Reliance Materials - LTLMGMT-00015394		Confidential
76.	Mullin Reliance Materials - LTLMGMT-00015451		Confidential
77.	Mullin Reliance Materials - LTLMGMT-00015455		Confidential
78.	Mullin Reliance Materials - LTLMGMT-00015459		Confidential
79.	Mullin Reliance Materials - LTLMGMT-00015612		Confidential
80.	Mullin Reliance Materials - LTLMGMT-00015613		Confidential
81.	Mullin Reliance Materials - LTLMGMT-00015648		Confidential
82.	Mullin Reliance Materials - LTLMGMT-00015668		Confidential
83.	Mullin Reliance Materials - LTLMGMT-00015682		Confidential
84.	Mullin Reliance Materials - LTLMGMT-00015718		Confidential
85.	Mullin Reliance Materials - LTLMGMT-00015729		Confidential
86.	Mullin Reliance Materials - LTLMGMT-00015745		Confidential
87.	Mullin Reliance Materials - LTLMGMT-00015848		Confidential
88.	Mullin Reliance Materials - LTLMGMT-00015859		Confidential
89.	Mullin Reliance Materials - LTLMGMT-00015880		Confidential
90.	Mullin Reliance Materials - LTLMGMT-00015917		Confidential
91.	Mullin Reliance Materials - LTLMGMT-00015952		Confidential
92.	Mullin Reliance Materials - LTLMGMT-00015974		Confidential
93.	Mullin Reliance Materials - LTLMGMT-00016011		Confidential
94.	Mullin Reliance Materials - LTLMGMT-00016036		Confidential
95.	Mullin Reliance Materials - LTLMGMT-00016058		Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
96.	Mullin Reliance Materials - LTLMGMT-00016080		Confidential
97.	Mullin Reliance Materials - LTLMGMT-00016101		Confidential
98.	Mullin Reliance Materials - LTLMGMT-00016124		Confidential
99.	Mullin Reliance Materials - LTLMGMT-00016150		Confidential
100.	Mullin Reliance Materials - LTLMGMT-00016184		Confidential
101.	Mullin Reliance Materials - LTLMGMT-00016251		Confidential
102.	Mullin Reliance Materials - LTLMGMT-00016271		Confidential
103.	Mullin Reliance Materials - LTLMGMT-00016291		Confidential
104.	Mullin Reliance Materials - LTLMGMT-00016313		Confidential
105.	Mullin Reliance Materials - LTLMGMT-00016334		Confidential
106.	Mullin Reliance Materials - LTLMGMT-00016335		Confidential
107.	Mullin Reliance Materials - LTLMGMT-00016345		Confidential
108.	Mullin Reliance Materials - LTLMGMT-00016346		Confidential
109.	Mullin Reliance Materials - LTLMGMT-00016507		Confidential
110.	Mullin Reliance Materials - LTLMGMT-00016557		Confidential
111.	Mullin Reliance Materials - LTLMGMT-00016610		Confidential
112.	Mullin Reliance Materials - LTLMGMT-00016669		Confidential
113.	Mullin Reliance Materials - LTLMGMT-00016680		Confidential
114.	Mullin Reliance Materials - LTLMGMT-00016682		Confidential
115.	Mullin Reliance Materials - LTLMGMT-00016693		Confidential
116.	Mullin Reliance Materials - LTLMGMT-00016696		Confidential
117.	Mullin Reliance Materials - LTLMGMT-00016698		Confidential
118.	Mullin Reliance Materials - LTLMGMT-00016706		Confidential
119.	Mullin Reliance Materials - LTLMGMT-00016709		Confidential
120.	Mullin Reliance Materials - LTLMGMT-00016711		Confidential
121.	Mullin Reliance Materials - LTLMGMT-00016717		Confidential
122.	Mullin Reliance Materials - LTLMGMT-00016720		Confidential
123.	Mullin Reliance Materials - LTLMGMT-00016723		Confidential
124.	Mullin Reliance Materials - LTLMGMT-00016725		Confidential
125.	Mullin Reliance Materials - LTLMGMT-00016727		Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
126.	Mullin Reliance Materials - LTLMGMT-00016736		Confidential
127.	Mullin Reliance Materials - LTLMGMT-00016739		Confidential
128.	Mullin Reliance Materials - LTLMGMT-00016742		Confidential
129.	Mullin Reliance Materials - LTLMGMT-00016753		Confidential
130.	Mullin Reliance Materials - LTLMGMT-00016761		Confidential
131.	Mullin Reliance Materials - LTLMGMT-00016768		Confidential
132.	Mullin Reliance Materials - LTLMGMT-00016770		Confidential
133.	Mullin Reliance Materials - LTLMGMT-00016774		Confidential
134.	Mullin Reliance Materials - LTLMGMT-00016777		Confidential
135.	Mullin Reliance Materials - LTLMGMT-00016783		Confidential
136.	Mullin Reliance Materials - LTLMGMT-00016785		Confidential
137.	Mullin Reliance Materials - LTLMGMT-00016793		Confidential
138.	Mullin Reliance Materials - LTLMGMT-00016799		Confidential
139.	Mullin Reliance Materials - LTLMGMT-00016802		Confidential
140.	Mullin Reliance Materials - LTLMGMT-00016885		Confidential
141.	Mullin Reliance Materials - LTLMGMT-00016887		Confidential
142.	Mullin Reliance Materials - LTLMGMT-00016890		Confidential
143.	Mullin Reliance Materials - LTLMGMT-00016892		Confidential
144.	Mullin Reliance Materials - LTLMGMT-00016899		Confidential
145.	Mullin Reliance Materials - LTLMGMT-00016906		Confidential
146.	Mullin Reliance Materials - LTLMGMT-00016914		Confidential
147.	Mullin Reliance Materials - LTLMGMT-00016917		Confidential
148.	Mullin Reliance Materials - LTLMGMT-00016926		Confidential
149.	Mullin Reliance Materials - LTLMGMT-00016928		Confidential
150.	Mullin Reliance Materials - LTLMGMT-00016930		Confidential
151.	Mullin Reliance Materials - LTLMGMT-00016932		Confidential
152.	Mullin Reliance Materials - LTLMGMT-00016935		Confidential
153.	Mullin Reliance Materials - LTLMGMT-00016937		Confidential
154.	Mullin Reliance Materials - LTLMGMT-00016940		Confidential
155.	Mullin Reliance Materials - LTLMGMT-00016949		Confidential



Ex.	Description	Beg. Bates No.	Confidential Designation
156.	Mullin Reliance Materials - LTLMGMT-00016956		Confidential
157.	Mullin Reliance Materials - LTLMGMT-00016959		Confidential
158.	Mullin Reliance Materials - LTLMGMT-00016961		Confidential
159.	Mullin Reliance Materials - LTLMGMT-00016964		Confidential
160.	Mullin Reliance Materials - LTLMGMT-00016971		Confidential
161.	Mullin Reliance Materials - LTLMGMT-00016973		Confidential
162.	Mullin Reliance Materials - LTLMGMT-00016981		Confidential
163.	Mullin Reliance Materials - LTLMGMT-00016983		Confidential
164.	Mullin Reliance Materials - LTLMGMT-00016986		Confidential
165.	Mullin Reliance Materials - LTLMGMT-00016993		Confidential
166.	Mullin Reliance Materials - LTLMGMT-00016998		Confidential
167.	Mullin Reliance Materials - LTLMGMT-00017001		Confidential
168.	Mullin Reliance Materials - LTLMGMT-00017003		Confidential
169.	Mullin Reliance Materials - LTLMGMT-00017005		Confidential
170.	Article entitled, “‘What Cancer Victim Would Agree to That?’: Opposition Brewing Over Talc Powder Deal” dated April 6, 2023		
171.	Article entitled, “\$8.9B Settlement: Attorney Helms Proposed Johnson & Johnson Talcum Powder Deal” dated April 4, 2023		
172.	Article entitled, “Cancer Victims Uniting to Oppose Johnson & Johnson’s Latest Bankruptcy Ploy” dated April 4, 2023		
173.	New York Times Article entitled, “Johnson & Johnson Reaches Deal for \$8.9 Billion Talc Settlement” dated April 4, 2023		
174.	Article entitled, “Leadership in Talc Litigation Ready to Resume Trials” dated April 4, 2023		
175.	Article entitled, “J&J Disguises Second Bankruptcy As Sham Settlement” dated April 5, 2023		
176.	Article entitled, “Beasley Allen/Ashcraft & Gerel Law Firms: Talc MDL Leadership Rejects Johnson & Johnson’s Second Attempt to Abuse Bankruptcy Process” dated April 6, 2023		
177.	Article entitled, “Cancer Victims’ Lawyers Vow to Fight J&J Proposed Settlement” dated April 6, 2023		

Ex.	Description	Beg. Bates No.	Confidential Designation
178.	Article entitled, “Johnson & Johnson’s \$8.9B bankruptcy settlement is ‘unworkable,’ talc plaintiff lawyer says” dated April 10, 2023		
179.	Article entitled, “J&J Unit Ch. 11 Judge Slows Pace on Renewed Dismissal Try” dated April 11, 2023		
180.	Article entitled, “Plaintiffs’ Steering Committee in the Federal Talc Multidistrict Litigation: Leadership in Talc MDL Litigation Applauds Sen. Durbin for Remarks in CNN Report” dated May 9, 2023		
181.	Official Committee of Talc Claimants webpage “About Us” page		
182.	Miller and Zois “Talcum Powder Lawsuit” webpage, June 2023 Update		
183.	Term Sheet with Exhibit A	LTLMGMT-00002628	Confidential
184.	310Ba - Worldwide Dividend Policy.docx	LTLMGMT-00013209	Confidential
185.	310Ga - Approved Borrowing Limits.docx	LTLMGMT-00013220	Confidential
186.	410Aa - Guidelines for Approvals.docx	LTLMGMT-00013227	Confidential
187.	410Ac - Approval Responsibilities for External Transactions.pdf	LTLMGMT-00013229	Confidential
188.	410Af - Approval Matrix for Internal Transactions and Reorganizations.xlsx	LTLMGMT-00013232	Confidential
189.	410Ba - Capital Appropriation Requests (1).pdf	LTLMGMT-00013233	Confidential
190.	420Ca - Licensing Merger and Acquisition Guidelines.pdf	LTLMGMT-00013246	Confidential
191.	JIFC to GTSC Loans.docx	LTLMGMT-00013257	Confidential
192.	210Ea – Intercompany Accounting Policy.pdf	LTLMGMT-00013258	Confidential
193.	Position Paper on Accounting and BRAVO Reporting for Cash Pooling.pdf	LTLMGMT-00013286	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
194.	310Ha – Borrowing Policy.pdf	LTLMGMT-00013289	Confidential
195.	Transfer pricing method determining intra-group debit and credit interest.pdf	LTLMGMT-00013299	Confidential
196.	230Cd – Divestiture Accounting Memo	LTLMGMT-00017054	Confidential
197.	410Ae – Deal Requirements Non-binding and Binding	LTLMGMT-00017065	Confidential
198.	Group Holdings Ownership Structure (2022)	LTLMGMT-00013206	Confidential
199.	J&J HoldCo (NA) Org Chart (February 2022)	LTLMGMT-00013207	Confidential
200.	2019 Financial Statement (JIFC).pdf	LTLMGMT-00005036- LTLMGMT-00005064	Confidential
201.	2020 Financial Statement (JIFC).pdf	LTLMGMT-00005065- LTLMGMT-00005098	Confidential
202.	2021 Financial Statement (JIFC).pdf	LTLMGMT-00005099- LTLMGMT-00005132	Confidential
203.	Apsis SAS (11.30.2022 Interim).pdf	LTLMGMT-00005133- LTLMGMT-00005145	Confidential
204.	Apsis SAS (2019).pdf	LTLMGMT-00005146-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00005175	
205.	Apsis SAS (2020).pdf	LTLMGMT-00005176- LTLMGMT-00005205	Confidential
206.	Apsis SAS (2021).pdf	LTLMGMT-00005206- LTLMGMT-00005239	Confidential
207.	Draft GH accounts November 22.xlsx	LTLMGMT-00005240- LTLMGMT-00005240	Confidential
208.	EIT Emerging Implant Technologies GmbH (2021).pdf	LTLMGMT-00005241- LTLMGMT-00005288	Confidential
209.	GH Bio 202 US GAAP TB.xlsx	LTLMGMT-00005289- LTLMGMT-00005289	Confidential
210.	GH Biotech Final signed accounts including signed audit opinion.pdf	LTLMGMT-00005290- LTLMGMT-00005322	Confidential
211.	GH Biotech FS FY19 - fully signed.pdf	LTLMGMT-00005323- LTLMGMT-00005358	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
212.	GH Biotech Holding Limited - Financial statements.pdf	LTLMGMT-00005359- LTLMGMT-00005390	Confidential
213.	Janssen Irish Finance Company UC - FRS 101 (EN) (2).pdf	LTLMGMT-00005391- LTLMGMT-00005424	Confidential
214.	Janssen-Cilag GmbH (2021).pdf	LTLMGMT-00005425- LTLMGMT-00005486	Confidential
215.	Janssen-Cilag SAS (10.3.2022 interim).pdf	LTLMGMT-00005487- LTLMGMT-00005501	Confidential
216.	Janssen-Cilag SAS (2019).pdf	LTLMGMT-00005502- LTLMGMT-00005532	Confidential
217.	Janssen-Cilag SAS (2020).pdf	LTLMGMT-00005533- LTLMGMT-00005564	Confidential
218.	Janssen-Cilag SAS (2021).pdf	LTLMGMT-00005565- LTLMGMT-00005600	Confidential
219.	JIFC to GTSC Loans.docx	LTLMGMT-00005601-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00005601	
220.	Johnson & Johnson Financial Services GmbH (2021).pdf	LTLMGMT-00005602- LTLMGMT-00005649	Confidential
221.	Johnson & Johnson Medical GmbH (2021).pdf	LTLMGMT-00005650- LTLMGMT-00005705	Confidential
222.	Johnson & Johnson Medical SAS (2019).pdf	LTLMGMT-00005706- LTLMGMT-00005742	Confidential
223.	Johnson & Johnson Medical SAS (2020).pdf	LTLMGMT-00005743- LTLMGMT-00005781	Confidential
224.	Johnson & Johnson Medical SAS (2021).pdf	LTLMGMT-00005782- LTLMGMT-00005821	Confidential
225.	JSI (2019_FS).pdf	LTLMGMT-00005822- LTLMGMT-00005871	Confidential
226.	JSI (2020_FS).pdf	LTLMGMT-00005872- LTLMGMT-00005925	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
227.	JSI (2021 FS).pdf	LTLMGMT-00005926- LTLMGMT-00005979	Confidential
228.	JSI 2022 Draft BS.xlsx	LTLMGMT-00005980- LTLMGMT-00005980	Confidential
229.	JSI US GAAP 2022 TB.xlsx	LTLMGMT-00005981- LTLMGMT-00005981	Confidential
230.	LE 7127 SFS 2019.pdf	LTLMGMT-00005982- LTLMGMT-00005992	Confidential
231.	LE 7127 SFS 2020.pdf	LTLMGMT-00005993- LTLMGMT-00006002	Confidential
232.	LE 7127 SFS 2021.pdf	LTLMGMT-00006003- LTLMGMT-00006013	Confidential
233.	LE 7905 SFS 2019.pdf	LTLMGMT-00006014- LTLMGMT-00006061	Confidential
234.	LE 7905 SFS 2020.pdf	LTLMGMT-00006062-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00006111	
235.	LE 7905 SFS 2021.pdf	LTLMGMT-00006112- LTLMGMT-00006159	Confidential
236.	LE 7930 SFS 2019.pdf	LTLMGMT-00006160- LTLMGMT-00006217	Confidential
237.	LE 7930 SFS 2020.pdf	LTLMGMT-00006218- LTLMGMT-00006275	Confidential
238.	LE 7930 SFS 2021.pdf	LTLMGMT-00006276- LTLMGMT-00006331	Confidential
239.	LE 7933 SFS 2019.pdf	LTLMGMT-00006332- LTLMGMT-00006374	Confidential
240.	LE 7933 SFS 2020.pdf	LTLMGMT-00006375- LTLMGMT-00006424	Confidential
241.	LE 7933 SFS 2021.pdf	LTLMGMT-00006425- LTLMGMT-00006472	Confidential



Ex.	Description	Beg. Bates No.	Confidential Designation
242.	LE 7941 SFS 2019.pdf	LTLMGMT-00006473- LTLMGMT-00006502	Confidential
243.	LE 7941 SFS 2020.pdf	LTLMGMT-00006503- LTLMGMT-00006536	Confidential
244.	LE 7941 SFS 2021.pdf	LTLMGMT-00006537- LTLMGMT-00006572	Confidential
245.	LE 8000 SFS 2019.pdf	LTLMGMT-00006573- LTLMGMT-00006636	Confidential
246.	LE 8000 SFS 2020.pdf	LTLMGMT-00006637- LTLMGMT-00006696	Confidential
247.	LE 8000 SFS 2021.pdf	LTLMGMT-00006697- LTLMGMT-00006758	Confidential
248.	Orthotaxy SAS (2019).PDF	LTLMGMT-00006759- LTLMGMT-00006831	Confidential
249.	Orthotaxy SAS (2020).pdf	LTLMGMT-00006832-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00006859	
250.	Orthotaxy SAS (2021).pdf	LTLMGMT-00006860- LTLMGMT-00006884	Confidential
251.	TB JIFC Q4 2022.xlsx	LTLMGMT-00006885- LTLMGMT-00006885	Confidential
252.	Draft GH accounts November 22.xlsx	LTLMGMT-00006886- LTLMGMT-00006886	Confidential
253.	GH Bio 202 US GAAP TB.xlsx	LTLMGMT-00006887- LTLMGMT-00006887	Confidential
254.	Janssen Irish Finance Company UC - FRS 101 (EN) (2).pdf	LTLMGMT-00006888- LTLMGMT-00006921	Confidential
255.	JSI 2022 Draft BS.xlsx	LTLMGMT-00006922- LTLMGMT-00006922	Confidential
256.	JSI US GAAP 2022 TB.xlsx	LTLMGMT-00006923- LTLMGMT-00006923	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
257.	TB JIFC Q4 2022.xlsx	LTLMGMT-00006924- LTLMGMT-00006924	Confidential
258.	7870 - APSIS- Interim FS as at 30.11.2022 Draft II.pdf	LTLMGMT-00006925- LTLMGMT-00006937	Confidential
259.	J&J - Project Diamond - FR - 03.19 - Janssen Cilag - Statutory Auditor Report Rapport Acompte sur Dividendes (PWC) (FR) - 13 Dec.pdf	LTLMGMT-00006938- LTLMGMT-00006952	Confidential
260.	J&J MEDICAL RCA 15.06.2022..pdf	LTLMGMT-00006953- LTLMGMT-00006992	Confidential
261.	ORTHOTAXY - Rapport sur les comptes annuels SAS .pdf	LTLMGMT-00006993- LTLMGMT-00007017	Confidential
262.	SE 2021_APSIS RCA 15.06.2022..pdf	LTLMGMT-00007018- LTLMGMT-00007051	Confidential
263.	SE 2022_JANSSEN CILAG Rapport Acompte sur Dividendes 13.12.2022.pdf	LTLMGMT-00007052- LTLMGMT-00007066	Confidential
264.	SE JANSSEN CILAG 2021 - RCA 16.06.2022..pdf	LTLMGMT-00007067-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00007102	
265.	Apsis SAS (11.30.2022 Interim).pdf	LTLMGMT-00007103- LTLMGMT-00007115	Confidential
266.	Apsis SAS (2019).pdf	LTLMGMT-00007116- LTLMGMT-00007145	Confidential
267.	Apsis SAS (2020).pdf	LTLMGMT-00007146- LTLMGMT-00007175	Confidential
268.	Apsis SAS (2021).pdf	LTLMGMT-00007176- LTLMGMT-00007209	Confidential
269.	Janssen-Cilag SAS (10.3.2022 interim).pdf	LTLMGMT-00007210- LTLMGMT-00007224	Confidential
270.	Janssen-Cilag SAS (2019).pdf	LTLMGMT-00007225- LTLMGMT-00007255	Confidential
271.	Janssen-Cilag SAS (2020).pdf	LTLMGMT-00007256- LTLMGMT-00007287	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
272.	Janssen-Cilag SAS (2021).pdf	LTLMGMT-00007288-LTLMGMT-00007323	Confidential
273.	Johnson & Johnson Medical SAS (2019).pdf	LTLMGMT-00007324-LTLMGMT-00007360	Confidential
274.	Johnson & Johnson Medical SAS (2020).pdf	LTLMGMT-00007361-LTLMGMT-00007399	Confidential
275.	Johnson & Johnson Medical SAS (2021).pdf	LTLMGMT-00007400-LTLMGMT-00007439	Confidential
276.	Orthotaxy SAS (2019).PDF	LTLMGMT-00007440-LTLMGMT-00007512	Confidential
277.	Orthotaxy SAS (2020).pdf	LTLMGMT-00007513-LTLMGMT-00007540	Confidential
278.	Orthotaxy SAS (2021).pdf	LTLMGMT-00007541-LTLMGMT-00007565	Confidential
279.	APSYS Déclaration BIC au 31_12_2020 11_05_2021 Signe MM.pdf	LTLMGMT-00007566-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00007596	
280.	APSYS - FY21 - CIT return - Efiled.pdf	LTLMGMT-00007597- LTLMGMT-00007628	Confidential
281.	Janssen Cilag - FY21 CIT return - Efiled.pdf	LTLMGMT-00007629- LTLMGMT-00007662	Confidential
282.	JANSSEN CILAG Déclaration BIC au 31_12_2020 11_05_2021.pdf	LTLMGMT-00007663- LTLMGMT-00007700	Confidential
283.	JOHNSON JOHNSON MEDICAL SAS Déclaration BIC au 31_12_2020 11_05_2021 signe MM.pdf	LTLMGMT-00007701- LTLMGMT-00007738	Confidential
284.	JOHNSON & JOHNSON MEDICAL SAS - FY21 CIT return - Efiled.pdf	LTLMGMT-00007739- LTLMGMT-00007775	Confidential
285.	ORTHOTAXY - FY21 CIT return - Efiled.pdf	LTLMGMT-00007776- LTLMGMT-00007799	Confidential
286.	ORTHOTAXY Déclaration BIC au 31_12_2020.pdf	LTLMGMT-00007800- LTLMGMT-00007825	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
287.	EIT JAP 2021 Bericht sig.pdf	LTLMGMT-00007826- LTLMGMT-00007873	Confidential
288.	J&J Financial Services JAP 2021 Bericht sig.pdf	LTLMGMT-00007874- LTLMGMT-00007921	Confidential
289.	J&J Medical JAP 2021 Bericht_sig.pdf	LTLMGMT-00007922- LTLMGMT-00007977	Confidential
290.	Janssen_Bericht_CONTENT_DEE00018280.1.1_525293_Endexemplar_20220923.pdf	LTLMGMT-00007978- LTLMGMT-00008039	Confidential
291.	Synthes Tutt JAP 2021 Bericht sig.pdf	LTLMGMT-00008040- LTLMGMT-00008083	Confidential
292.	AW_Financials.msg	LTLMGMT-00008084- LTLMGMT-00008087	Confidential
293.	LE 7126 SFS 2019.pdf	LTLMGMT-00008088- LTLMGMT-00008095	Confidential
294.	LE 7126 SFS 2020.pdf	LTLMGMT-00008096-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00008103	
295.	LE 7126 SFS 2021.pdf	LTLMGMT-00008104- LTLMGMT-00008112	Confidential
296.	LE 7126 Tax Return 2019.pdf	LTLMGMT-00008113- LTLMGMT-00008164	Confidential
297.	LE 7126 Tax Return 2020.pdf	LTLMGMT-00008165- LTLMGMT-00008213	Confidential
298.	LE 7126 Tax Return 2021 - DRAFT.pdf	LTLMGMT-00008214- LTLMGMT-00008225	Confidential
299.	LE 7127 SFS 2019.pdf	LTLMGMT-00008226- LTLMGMT-00008236	Confidential
300.	LE 7127 SFS 2020.pdf	LTLMGMT-00008237- LTLMGMT-00008246	Confidential
301.	LE 7127 SFS 2021.pdf	LTLMGMT-00008247- LTLMGMT-00008257	Confidential



Ex.	Description	Beg. Bates No.	Confidential Designation
302.	LE 7127 Tax Return 2019 Part 1.pdf	LTLMGMT-00008258- LTLMGMT-00008265	Confidential
303.	LE 7127 Tax Return 2019 Part 2.pdf	LTLMGMT-00008266- LTLMGMT-00008305	Confidential
304.	LE 7127 Tax Return 2020.pdf	LTLMGMT-00008306- LTLMGMT-00008350	Confidential
305.	LE 7127 Tax Return 2021 - DRAFT.pdf	LTLMGMT-00008351- LTLMGMT-00008359	Confidential
306.	LE 7141 SFS 2019.pdf	LTLMGMT-00008360- LTLMGMT-00008363	Confidential
307.	LE 7141 SFS 2020.pdf	LTLMGMT-00008364- LTLMGMT-00008367	Confidential
308.	LE 7141 SFS 2021.pdf	LTLMGMT-00008368- LTLMGMT-00008371	Confidential
309.	LE 7141 Tax Return 2019 Part 1.pdf	LTLMGMT-00008372-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00008409	
310.	LE 7141 Tax Return 2019 Part 2.pdf	LTLMGMT-00008410- LTLMGMT-00008416	Confidential
311.	LE 7141 Tax Return 2020 Part 1.pdf	LTLMGMT-00008417- LTLMGMT-00008452	Confidential
312.	LE 7141 Tax Return 2020 Part 2.pdf	LTLMGMT-00008453- LTLMGMT-00008460	Confidential
313.	Johnson & Johnson Financial Services GmbH (2021).pdf	LTLMGMT-00008461- LTLMGMT-00008508	Confidential
314.	LE 7905 SFS 2019.pdf	LTLMGMT-00008509- LTLMGMT-00008556	Confidential
315.	LE 7905 SFS 2020.pdf	LTLMGMT-00008557- LTLMGMT-00008606	Confidential
316.	LE 7905 SFS 2021.pdf	LTLMGMT-00008607- LTLMGMT-00008654	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
317.	LE 7905 Tax Return 2019.pdf	LTLMGMT-00008655- LTLMGMT-00008705	Confidential
318.	LE 7905 Tax Return 2020.pdf	LTLMGMT-00008706- LTLMGMT-00008753	Confidential
319.	LE 7905 Tax Return 2021 - DRAFT.pdf	LTLMGMT-00008754- LTLMGMT-00008805	Confidential
320.	Johnson & Johnson Medical GmbH (2021).pdf	LTLMGMT-00008806- LTLMGMT-00008861	Confidential
321.	LE 7930 SFS 2019.pdf	LTLMGMT-00008862- LTLMGMT-00008919	Confidential
322.	LE 7930 SFS 2020.pdf	LTLMGMT-00008920- LTLMGMT-00008977	Confidential
323.	LE 7930 SFS 2021.pdf	LTLMGMT-00008978- LTLMGMT-00009033	Confidential
324.	LE 7930 Tax Return 2019.pdf	LTLMGMT-00009034-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00009086	
325.	LE 7930 Tax Return 2020.pdf	LTLMGMT-00009087- LTLMGMT-00009134	Confidential
326.	LE 7930 Tax Return 2021.pdf	LTLMGMT-00009135- LTLMGMT-00009185	Confidential
327.	LE 7932 SFS 2019.pdf	LTLMGMT-00009186- LTLMGMT-00009195	Confidential
328.	LE 7932 SFS 2020.pdf	LTLMGMT-00009196- LTLMGMT-00009205	Confidential
329.	LE 7932 SFS 2021.pdf	LTLMGMT-00009206- LTLMGMT-00009215	Confidential
330.	LE 7932 Tax Return 2019.pdf	LTLMGMT-00009216- LTLMGMT-00009260	Confidential
331.	LE 7932 Tax Return 2020.pdf	LTLMGMT-00009261- LTLMGMT-00009303	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
332.	EIT Emerging Implant Technologies GmbH (2021).pdf	LTLMGMT-00009304- LTLMGMT-00009351	Confidential
333.	LE 7933 SFS 2019.pdf	LTLMGMT-00009352- LTLMGMT-00009394	Confidential
334.	LE 7933 SFS 2020.pdf	LTLMGMT-00009395- LTLMGMT-00009444	Confidential
335.	LE 7933 SFS 2021.pdf	LTLMGMT-00009445- LTLMGMT-00009492	Confidential
336.	LE 7933 Tax Return 2019.pdf	LTLMGMT-00009493- LTLMGMT-00009539	Confidential
337.	LE 7933 Tax Return 2020.pdf	LTLMGMT-00009540- LTLMGMT-00009580	Confidential
338.	LE 7941 SFS 2019.pdf	LTLMGMT-00009581- LTLMGMT-00009610	Confidential
339.	LE 7941 SFS 2020.pdf	LTLMGMT-00009611-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00009644	
340.	LE 7941 SFS 2021.pdf	LTLMGMT-00009645- LTLMGMT-00009680	Confidential
341.	LE 7941 Tax Return 2019.pdf	LTLMGMT-00009681- LTLMGMT-00009751	Confidential
342.	LE 7941 Tax Return 2020.pdf	LTLMGMT-00009752- LTLMGMT-00009825	Confidential
343.	LE 7941 Tax Return 2021.pdf	LTLMGMT-00009826- LTLMGMT-00009912	Confidential
344.	LE 7955 SFS 2019.pdf	LTLMGMT-00009913- LTLMGMT-00009921	Confidential
345.	LE 7955 SFS 2020.pdf	LTLMGMT-00009922- LTLMGMT-00009930	Confidential
346.	LE 7955 SFS 2021.pdf	LTLMGMT-00009931- LTLMGMT-00009941	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
347.	LE 7955 Tax Return 2019.pdf	LTLMGMT-00009942- LTLMGMT-00009990	Confidential
348.	LE 7955 Tax Return 2020.pdf	LTLMGMT-00009991- LTLMGMT-00010035	Confidential
349.	LE 7955 Tax Return 2021 - DRAFT.pdf	LTLMGMT-00010036- LTLMGMT-00010044	Confidential
350.	Janssen-Cilag GmbH (2021).pdf	LTLMGMT-00010045- LTLMGMT-00010106	Confidential
351.	LE 8000 SFS 2019.pdf	LTLMGMT-00010107- LTLMGMT-00010170	Confidential
352.	LE 8000 SFS 2020.pdf	LTLMGMT-00010171- LTLMGMT-00010230	Confidential
353.	LE 8000 SFS 2021.pdf	LTLMGMT-00010231- LTLMGMT-00010292	Confidential
354.	LE 8000 Tax Return 2019 Part 1.pdf	LTLMGMT-00010293-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00010331	
355.	LE 8000 Tax Return 2019 Part 2.pdf	LTLMGMT-00010332- LTLMGMT-00010338	Confidential
356.	LE 8000 Tax Return 2020.pdf	LTLMGMT-00010339- LTLMGMT-00010386	Confidential
357.	LE 8000 Tax Return 2021.pdf	LTLMGMT-00010387- LTLMGMT-00010437	Confidential
358.	2017 Signed Financial Statements GH Biotech Holdings Limited.pdf	LTLMGMT-00010438- LTLMGMT-00010463	Confidential
359.	GH Biotech Final signed accounts including signed audit opinion.pdf	LTLMGMT-00010464- LTLMGMT-00010496	Confidential
360.	GH Biotech FS FY19 - fully signed.pdf	LTLMGMT-00010497- LTLMGMT-00010532	Confidential
361.	GH Biotech Holding Limited - Financial statements.pdf	LTLMGMT-00010533- LTLMGMT-00010564	Confidential



Ex.	Description	Beg. Bates No.	Confidential Designation
362.	Signed 2018 Financial Statements GH Biotech.pdf	LTLMGMT-00010565- LTLMGMT-00010597	Confidential
363.	2017 Signed Financial Statements Janssen Sciences Ireland UC.pdf	LTLMGMT-00010598- LTLMGMT-00010644	Confidential
364.	2018 Signed Financial Statements JSI.pdf	LTLMGMT-00010645- LTLMGMT-00010692	Confidential
365.	7566 Janssen Sciences Ireland Unlimited Company - signed 2020.pdf	LTLMGMT-00010693- LTLMGMT-00010746	Confidential
366.	7566 Janssen Sciences Ireland Unlimited Company Signed Accs 2021.pdf	LTLMGMT-00010747- LTLMGMT-00010800	Confidential
367.	JSI Signed Financial statements FY19 (FINAL).pdf	LTLMGMT-00010801- LTLMGMT-00010850	Confidential
368.	2018 signed Financial Satements Janssen Biologics .pdf	LTLMGMT-00010851- LTLMGMT-00010872	Confidential
369.	Janssen Biologics - Signed financial statements FY21.pdf	LTLMGMT-00010873-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00010893	
370.	Janssen Biologics Signed Accounts FY17.pdf	LTLMGMT-00010894- LTLMGMT-00010923	Confidential
371.	JBI signed accounts 29.12.2019.pdf	LTLMGMT-00010924- LTLMGMT-00010945	Confidential
372.	JBI Signed accounts including signed audit opinion FY21.pdf	LTLMGMT-00010946- LTLMGMT-00010967	Confidential
373.	8136-Janssen Development Finance Unlimited Company - Draft-V updated final signed_ (002) (1).pdf	LTLMGMT-00010968- LTLMGMT-00010994	Confidential
374.	JDF.pdf	LTLMGMT-00010995- LTLMGMT-00011028	Confidential
375.	2017 Janssen Irish Finance Company Financial Statements (signed by directors).pdf	LTLMGMT-00011029- LTLMGMT-00011051	Confidential
376.	8189 JIFC- JJ Finance Treasury Unlimited UC - 2019 Draft V updated (003)-signed final_ (1).pdf	LTLMGMT-00011052- LTLMGMT-00011080	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
377.	Janssen Irish Finance Company UC final signed 2021.pdf	LTLMGMT-00011081- LTLMGMT-00011114	Confidential
378.	JIFC.pdf	LTLMGMT-00011115- LTLMGMT-00011148	Confidential
379.	Signed 2018 Financial Statements Janssen Irish Finance Company.pdf	LTLMGMT-00011149- LTLMGMT-00011172	Confidential
380.	2017 Signed Financial Statements Janssen R&D Ireland.pdf	LTLMGMT-00011173- LTLMGMT-00011194	Confidential
381.	2018 signed Financial Statements Janssen R&D.pdf	LTLMGMT-00011195- LTLMGMT-00011218	Confidential
382.	Janssen R&D - Signed Financial Statements.pdf	LTLMGMT-00011219- LTLMGMT-00011242	Confidential
383.	Janssen R&D signed accounts 29.12.19.pdf	LTLMGMT-00011243- LTLMGMT-00011264	Confidential
384.	Janssen RD Ireland signed financial statements.pdf	LTLMGMT-00011265-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00011287	
385.	Royalty A&M five-year cashflow projection	LTL-0029874	Confidential
386.	Holdco Organizational Chart	LTLMGMT-00013207	Confidential
387.	Holdco legal entities and valuations	LTLMGMT-00014004	Confidential
388.	JJFC loans to Global Treasury Services Center ("GTSC")	LTLMGMT-00013257	Confidential
389.	KPMG summary of GH Biotech legal entities fair market value	LTLMGMT-00014005	Confidential
390.	Holdco dividends	LTLMGMT-00013463	Confidential
391.	J&J Worldwide Dividend Policy	LTLMGMT-00013209	Confidential
392.	J&J and Holdco Facility Agreement*	LTLMGMT-00017069	Confidential
393.	7 - LTL0030450_LTL0030207-LTL0031327 (JJCI Valuation).pdf	LTLMGMT-00011288-LTLMGMT-00011292	Confidential
394.	GH Biotech Valuation Schedules (Jan 2022 report).pdf	LTLMGMT-00011293-LTLMGMT-00011338	Confidential
395.	JJ HoldCo NA Chart (prelim valuations) (1).xlsx	LTLMGMT-00011339-LTLMGMT-00011339	Confidential
396.	LE7825_Pharmaceutical Carveout of Janssen-Cilag_Batch 3_DRAFT FMV Exhibits_12.7.2022.pdf	LTLMGMT-00011340-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00011345	
397.	135695 4 Amended Constitution of GH Biotech.PDF	LTLMGMT-00011346- LTLMGMT-00011382	Confidential
398.	135973 Plato - Item 1 1 2 - Bylaws of Currahee Holdco.PDF	LTLMGMT-00011383- LTLMGMT-00011395	Confidential
399.	190909 2019 GTSC - JIFC renewal.pdf	LTLMGMT-00011396- LTLMGMT-00011409	Confidential
400.	20211012 JIFC - GTSC Facility Agreement F.pdf	LTLMGMT-00011410- LTLMGMT-00011421	Confidential
401.	APSYS - 7870 - Updated AOA 31 12 18.pdf	LTLMGMT-00011422- LTLMGMT-00011428	Confidential
402.	GH Biotech Holdings Limited - Amended Constitution - 7 July 2021.PDF	LTLMGMT-00011429- LTLMGMT-00011502	Confidential
403.	Janssen Irish Finance Company UC - Constitution as amended by special resolution - 24 November 2021.PDF	LTLMGMT-00011503- LTLMGMT-00011543	Confidential
404.	Janssen Sciences Ireland UC - Constitution as amended by name change - 4 October 2018.pdf	LTLMGMT-00011544- LTLMGMT-00011581	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
405.	JIFC ETC - 2022 Amended and Restated Facility.pdf	LTLMGMT-00011582- LTLMGMT-00011591	Confidential
406.	Johnson & Johnson GmbH - 7941 - AoA Johnson & Johnson Holding GmbH 14.01.2019.pdf	LTLMGMT-00011592- LTLMGMT-00011599	Confidential
407.	JSI (constitution).pdf	LTLMGMT-00011600- LTLMGMT-00011637	Confidential
408.	2019 LE 6093 W140 Urban Renewal P&L.xls	LTLMGMT-00011638- LTLMGMT-00011638	Confidential
409.	2019 Tax Return (JIFC).pdf	LTLMGMT-00011639- LTLMGMT-00011655	Confidential
410.	2019 Tax Return (JSI).pdf	LTLMGMT-00011656- LTLMGMT-00011678	Confidential
411.	2019 Urban Renewal 1065 9 9 2020 Signed 001.pdf	LTLMGMT-00011679- LTLMGMT-00011702	Confidential
412.	2019-6093 balance sheet.pdf	LTLMGMT-00011703- LTLMGMT-00011703	Confidential
413.	2020 1065 Urban Final.pdf	LTLMGMT-00011704-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00011734	
414.	2020 LE 6093_W140 Urban Renewal P&L.xls	LTLMGMT-00011735- LTLMGMT-00011735	Confidential
415.	2020 Tax Return (JIFC).pdf	LTLMGMT-00011736- LTLMGMT-00011751	Confidential
416.	2020 Tax Return (JSI).pdf	LTLMGMT-00011752- LTLMGMT-00011774	Confidential
417.	2020-6093 balance sheet.pdf	LTLMGMT-00011775- LTLMGMT-00011775	Confidential
418.	2021 2550 Urban 1065 Final.pdf	LTLMGMT-00011776- LTLMGMT-00011802	Confidential
419.	2021 LE 6093_W140 Urban Renewal P&L.xls	LTLMGMT-00011803- LTLMGMT-00011803	Confidential
420.	2021 Tax Return (JIFC).pdf	LTLMGMT-00011804- LTLMGMT-00011818	Confidential
421.	2021 Tax Return (JSI).pdf	LTLMGMT-00011819- LTLMGMT-00011840	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
422.	2021-6093 balance sheet.pdf	LTLMGMT-00011841-LTLMGMT-00011841	Confidential
423.	2022 LE 6093 W140 Urban Renewal P&L.xls	LTLMGMT-00011842-LTLMGMT-00011842	Confidential
424.	2022-6093 balance sheet.pdf	LTLMGMT-00011843-LTLMGMT-00011843	Confidential
425.	APSYS Déclaration BIC au 31 12 2020 11 05 2021 Signe MM.pdf	LTLMGMT-00011844-LTLMGMT-00011874	Confidential
426.	Apsis (2020).pdf	LTLMGMT-00011875-LTLMGMT-00011905	Confidential
427.	Apsis (2021).pdf	LTLMGMT-00011906-LTLMGMT-00011937	Confidential
428.	APSYS - FY21 - CIT return - Efiled.pdf	LTLMGMT-00011938-LTLMGMT-00011969	Confidential
429.	J&J Medical SAS (2020).pdf	LTLMGMT-00011970-LTLMGMT-00012007	Confidential
430.	J&J Medical SAS (2021).pdf	LTLMGMT-00012008-	Confidential



Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00012044	
431.	Janssen Cilag (2020).pdf	LTLMGMT-00012045- LTLMGMT-00012082	Confidential
432.	Janssen Cilag (2021).pdf	LTLMGMT-00012083- LTLMGMT-00012116	Confidential
433.	Janssen Cilag - FY21 CIT return - Efiled.pdf	LTLMGMT-00012117- LTLMGMT-00012150	Confidential
434.	JANSSEN CILAG Déclaration BIC au 31_12_2020 11_05_2021.pdf	LTLMGMT-00012151- LTLMGMT-00012188	Confidential
435.	JOHNSON JOHNSON MEDICAL SAS Déclaration BIC au 31_12_2020 11_05_2021 signe MM.pdf	LTLMGMT-00012189- LTLMGMT-00012226	Confidential
436.	JOHNSON & JOHNSON MEDICAL SAS - FY21 CIT return - Efiled.pdf	LTLMGMT-00012227- LTLMGMT-00012263	Confidential
437.	LE 7127 Tax Return 2019 Part 1.pdf	LTLMGMT-00012264- LTLMGMT-00012271	Confidential
438.	LE 7127 Tax Return 2019 Part 2.pdf	LTLMGMT-00012272- LTLMGMT-00012311	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
439.	LE 7127 Tax Return 2020.pdf	LTLMGMT-00012312- LTLMGMT-00012356	Confidential
440.	LE 7127 Tax Return 2021 - DRAFT.pdf	LTLMGMT-00012357- LTLMGMT-00012365	Confidential
441.	LE 7905 Tax Return 2019.pdf	LTLMGMT-00012366- LTLMGMT-00012416	Confidential
442.	LE 7905 Tax Return 2020.pdf	LTLMGMT-00012417- LTLMGMT-00012464	Confidential
443.	LE 7905 Tax Return 2021 - DRAFT.pdf	LTLMGMT-00012465- LTLMGMT-00012516	Confidential
444.	LE 7930 Tax Return 2019.pdf	LTLMGMT-00012517- LTLMGMT-00012569	Confidential
445.	LE 7930 Tax Return 2020.pdf	LTLMGMT-00012570- LTLMGMT-00012617	Confidential
446.	LE 7930 Tax Return 2021.pdf	LTLMGMT-00012618- LTLMGMT-00012668	Confidential
447.	LE 7933 Tax Return 2019.pdf	LTLMGMT-00012669-	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
		LTLMGMT-00012715	
448.	LE 7933 Tax Return 2020.pdf	LTLMGMT-00012716- LTLMGMT-00012756	Confidential
449.	LE 7941 Tax Return 2019.pdf	LTLMGMT-00012757- LTLMGMT-00012827	Confidential
450.	LE 7941 Tax Return 2020.pdf	LTLMGMT-00012828- LTLMGMT-00012901	Confidential
451.	LE 7941 Tax Return 2021.pdf	LTLMGMT-00012902- LTLMGMT-00012988	Confidential
452.	LE 8000 Tax Return 2019 Part 1.pdf	LTLMGMT-00012989- LTLMGMT-00013027	Confidential
453.	LE 8000 Tax Return 2019 Part 2.pdf	LTLMGMT-00013028- LTLMGMT-00013034	Confidential
454.	LE 8000 Tax Return 2020.pdf	LTLMGMT-00013035- LTLMGMT-00013082	Confidential
455.	LE 8000 Tax Return 2021.pdf	LTLMGMT-00013083- LTLMGMT-00013133	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
456.	ORTHOTAXY - FY21 CIT return - Efiled.pdf	LTLMGMT-00013134-LTLMGMT-00013157	Confidential
457.	ORTHOTAXY Déclaration BIC au 31_12_2020.pdf	LTLMGMT-00013158-LTLMGMT-00013183	Confidential
458.	310Ba - Worldwide Dividend Policy.docx	LTLMGMT-00013184-LTLMGMT-00013194	Confidential
459.	LTL 0029900 .pdf	LTLMGMT-00013195-LTLMGMT-00013205	Confidential
460.	JJ Holdco chart 5.10.23.xlsx	LTLMGMT-00013208	Confidential
461.	Beasley Allen's Responses and Objections to the Debtor's First Document Requests		
462.	Beasley Allen's production in response to the Debtor's First Document Requests		
463.	Kazan McClain's Responses and Objections to the Debtor's First Document Requests and First Set of Interrogatories		
464.	Kazan McClain's Production in response to the Debtor's First Document Requests		
465.	Ashcraft & Gerel's Responses and Objections to the Debtor's First Document Requests		
466.	Barnes Law Group's Responses and Objections to the Debtor's First Document Requests		
467.	Barnes Law Group's Production in response to the Debtor's First Document Requests		
468.	Dean Omar's Responses and Objections to the Debtor's Subpoena		

Ex.	Description	Beg. Bates No.	Confidential Designation
469.	Levy Konigsberg Responses and Objections to the Debtor's First Document Requests		
470.	Arnold & Itkin's Responses and Objections to the Debtor's First Document Requests		
471.	Maune Raichle's Responses and Objections to the Debtor's First Document Requests and First Set of Interrogatories		
472.	Ruckdeschel's Responses and Objections to the Debtor's First Document Requests and First Set of Interrogatories		
473.	TCC's Responses and Objections to the Debtor's First Document Requests		
474.	TCC's production in response to the Debtor's First Document Requests		
475.	Ad Hoc Committee of States' Responses and Objections to the Debtor's First Document Requests		
476.	Ad Hoc Committee of States' production in response to the Debtor's First Document Requests		
477.	Dean Omar's Responses and Objections to the Debtor's First Document Requests		
478.	Ad Hoc Committee of States' Responses and Objections to the Debtor's First Set of Interrogatories and Executed Verification		
479.	Dean Omar's Responses and Objections to the Debtor's First Set of Interrogatories		
480.	Beasley Allen's Responses and Objections to the Debtor's First Set of Interrogatories		
481.	TCC's Verified Responses and Objections to the Debtor's First Set of Interrogatories		
482.	Arnold & Itkin's Responses and Objections to the Debtor's First Set of Interrogatories		
483.	TCC's Verified Supplemental Responses to Debtor's Interrogatory Nos. 6 & 8		
484.	Second Supplemental Responses and Objections to Interrogatory Nos. 2, 4, and 10 in the Debtor's First Set of Interrogatories to the Official Committee of Talc Claimants, dated June 23, 2023		
485.	Supplemental Responses and Objections to the Debtor's First Set of Requests for Production of Documents to the Official Committee of Talc Claimants, dated June 23, 2023		

Ex.	Description	Beg. Bates No.	Confidential Designation
486.	First Supplemental Verified Statement of Paul Hastings LLP, Cole Schotz P.C. and Parkins & Rubio LLP Pursuant to Bankruptcy Rule 2019 (Dkt. 807, 23-12825-MBK)		
487.	<i>Bestwall</i> (No. 17-31795-LTB, Bankr. W.D.N.C.), January 19, 2022 Hearing Transcript		
488.	<i>Bestwall</i> (No. 17-31795-LTB, Bankr. W.D.N.C.), March 3, 2023 Hearing Transcript		
489.	<i>Bestwall</i> (No. 17-31795-LTB, Bankr. W.D.N.C.), April 6, 2022 Hearing Transcript		
490.	<i>Bestwall</i> (No. 17-31795-LTB, Bankr. W.D.N.C.), September 19, 2019 Hearing Transcript		
491.	<i>Bestwall</i> (No. 17-31795-LTB, Bankr. W.D.N.C.), September 24, 2020 Hearing Transcript		
492.	Lisman Deposition Exhibit 8		
493.	2021-01-28 – Imerys 9 <sup>th</sup> Amended Plan and TDPs		
494.	November 4, 2021 Hearing Transcript (Witness Testimony Portion)		
495.	November 5, 2021 Hearing Transcript (Witness Testimony Portion)		
496.	February 14, 2022 Hearing Transcript (Witness Testimony Portion)		
497.	February 15, 2022 Hearing Transcript (Witness Testimony Portion)		
498.	February 16, 2022 Hearing Transcript (Witness Testimony Portion)		
499.	February 17, 2022 AM Hearing Transcript (Witness Testimony Portion)		
500.	February 17, 2022 PM Hearing Transcript (Witness Testimony Portion)		
501.	February 18, 2022 Hearing Transcript (Witness Testimony Portion)		
502.	April 18, 2023 Hearing Transcript (Witness Testimony Portion)		
503.	Email from Dwoskin to Rasmussen RE “LTL – open discovery items,” dated June 23, 2023		
504.	4-17-2023 Birchfield Deposition Exhibit 1		
505.	4-17-2023 Birchfield Deposition Exhibit 2		
506.	4-17-2023 Birchfield Deposition Exhibit 3		
507.	4-17-2023 Birchfield Deposition Exhibit 4		
508.	4-17-2023 Birchfield Deposition Exhibit 5		
509.	4-17-2023 Birchfield Deposition Exhibit 6		

Ex.	Description	Beg. Bates No.	Confidential Designation
510.	4-17-2023 Birchfield Deposition Exhibit 7		
511.	4-17-2023 Birchfield Deposition Exhibit 8		
512.	5-30-2023 Birchfield Deposition Exhibit 1		
513.	5-30-2023 Birchfield Deposition Exhibit 2		
514.	5-30-2023 Birchfield Deposition Exhibit 3		
515.	5-30-2023 Birchfield Deposition Exhibit 4		
516.	5-30-2023 Birchfield Deposition Exhibit 5		
517.	Compass Lexecon memo to Brown Rudnick re: “Duplication of Records in PSA Claimant and Ad Hoc Committee Lists,” dated June 23, 2023		
518.	Apsis – J&J HoldCo – JNJ – Letter of direction in respect of intercompany funding flows	LTLMGMT-00017082	Confidential
519.	J&J HoldcoNA (Lender) and JNJ (Borrower) – Draw Down 2023	LTLMGMT-00017067	Confidential
520.	Apsis – Minutes of the sole shareholder’s decision (approval FY 2022) – CMS review 21062023	LTLMGMT-00017090	Confidential
521.	2_Shareholders_Resolution_Johnson_Johnson_Holding_Distribution_Oppenhoff	LTLMGMT-00017086	Confidential
522.	First Monthly Fee Statement of FTI Consulting (Dkt. 1685, No. 21-30589-MBK))		
523.	Second Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 2069, No. 21-30589-MBK)		
524.	First Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 2167, No. 21-30589-MBK)		
525.	Third Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 2422, No. 21-30589-MBK)		
526.	Fourth Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 2501, No. 21-30589-MBK)		
527.	Fifth Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 2571, No. 21-30589-MBK)		
528.	Second Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 2591, No. 21-30589-MBK)		

Ex.	Description	Beg. Bates No.	Confidential Designation
529.	Sixth Monthly Fee Statement of Houlihan Lokey Capital, Inc. (Dkt. 2628, No. 21-30589-MBK)		
530.	Third Monthly Fee Statement for the Brattle Group, Inc. (Dkt. 2651, No. 21-30589-MBK))		
531.	Fourth Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 2658, No. 21-30589-MBK)		
532.	Fourth Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 2795, No. 21-30589-MBK)		
533.	Sixth Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 2797, No. 21-30589-MBK)		
534.	Sixth Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 2944, No. 21-30589-MBK)		
535.	Seventh Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 3061, No. 21-30589-MBK)		
536.	Seventh Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 3095, No. 21-30589-MBK)		
537.	Eighth Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 3209, No. 21-30589-MBK)		
538.	Tenth Monthly Fee Statement of Houlihan Lokey Capital, Inc. (Dkt. 3262, No. 21-30589-MBK)		
539.	Eighth Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 3265, No. 21-30589-MBK)		
540.	Ninth Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 3268, No. 21-30589-MBK)		
541.	Tenth Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 3346, No. 21-30589-MBK)		
542.	Ninth Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 3364, No. 21-30589-MBK)		
543.	Fee Application Cover Sheet the Period June 1, 2022 through September 30, 2022 for the Brattle Group, Inc. (Dkt. 3387, No. 21-30589-MBK)		



Ex.	Description	Beg. Bates No.	Confidential Designation
544.	Third Interim Fee Application of FTI Consulting, Inc. (Dkt. 3390, No. 21-30589-MBK)		
545.	Tenth Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 3492, No. 21-30589-MBK)		
546.	Eleventh Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 3543, No. 21-30589-MBK)		
547.	Eleventh Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 3654, No. 21-30589-MBK)		
548.	Twelfth Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 3705, No. 21-30589-MBK)		
549.	Twelfth Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 3799, No. 21-30589-MBK)		
550.	Thirteenth Monthly Fee Statement of the Brattle Group, Inc. (Dkt. 3868, No. 21-30589-MBK)		
551.	Thirteenth Monthly Fee Statement of FTI Consulting, Inc. (Dkt. 3892, No. 21-30589-MBK)		
552.	LTL II – Summary Exhibit re Claims Estimation		
553.	TCC’s Exclusivity Slides from June 13, 2023 Hr’g		
554.	Barnes Law Group’s Second Supplemental Response to the Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Bankruptcy Case (or Adversary Proceeding), dated June 22, 2023		
555.	Weitz & Luxenberg, PC’s Response and Objections to Request for Production No. 1 in the Debtor’s Request for Production, dated June 22, 2023		
556.	Levy Konigsberg Letter to Mark Rasmussen, Esq. re Response to Interrogatory No. 1, dated June 21, 2023		
557.	Dean Omar’s Supplemental Response to Debtor’s First Set of Interrogatories to Dean Omar Branham Shirley, LLP and Dean Omar Branham Shirley, LLP Acting for Dean Omar Talc Claimants, dated June 23, 2023		
558.	Arnold & Itkin’s Supplemental Response to Interrogatory No. 1, dated June 23, 2023		
559.	MRHFM Verified 2019.1 Disclosure		

Ex.	Description	Beg. Bates No.	Confidential Designation																																																														
560.	2023-05-22 Ruckdeschel Letter to Wall regarding discovery																																																																
561.	Amended Chapter 11 Plan (Dkt. 912, 23-12825-MBK)																																																																
562.	Redlines of Amended Plan and Exhibits in Support of Amended Chapter 11 Plan (Dkt. 913, 23-12825-MBK)																																																																
Exhibits from Motion to Dismiss Hearing in LTL 1																																																																	
MTD1 – Debtor’s Exhibit 1	Exhibit 1 contains the 2021 Corporate Restructuring closing binder, which includes eighty individual documents. For ease of reference, the Debtor provides the following chart to identify each document in the closing binder by Bates number.	LTL 0001058- LTL 0003086																																																															
	Ex. 1.1			LTL 0001058	LTL 0001061	Ex. 1.2	LTL 0001062	LTL 0001074	Ex. 1.3	LTL 0001075	LTL 0001076	Ex. 1.4	LTL 0001077	LTL 0001078	Ex. 1.5	LTL 0001079	LTL 0001091	Ex. 1.6	LTL 0001092	LTL 0001111	Ex. 1.7	LTL 0001112	LTL 0001113	Ex. 1.8	LTL 0001114	LTL 0001115	Ex. 1.9	LTL 0001116	LTL 0001119	Ex. 1.10	LTL 0001120	LTL 0001134	Ex. 1.11	LTL 0001135	LTL 0001144	Ex. 1.12	LTL 0001145	LTL 0001146	Ex. 1.13	LTL 0001147	LTL 0001150	Ex. 1.14	LTL 0001151	LTL 0001158	Ex. 1.15	LTL 0001159	LTL 0001176	Ex. 1.16	LTL 0001177	LTL 0001191	Ex. 1.17	LTL 0001192	LTL 0001204	Ex. 1.18	LTL 0001205	LTL 0001221	Ex. 1.19	LTL 0001222	LTL 0001234	Ex. 1.20	LTL 0001235	LTL 0001254	Ex. 1.21	LTL 0001255	LTL 0001266
	Ex. 1.1			LTL 0001058	LTL 0001061																																																												
	Ex. 1.2			LTL 0001062	LTL 0001074																																																												
	Ex. 1.3			LTL 0001075	LTL 0001076																																																												
	Ex. 1.4			LTL 0001077	LTL 0001078																																																												
	Ex. 1.5			LTL 0001079	LTL 0001091																																																												
	Ex. 1.6			LTL 0001092	LTL 0001111																																																												
	Ex. 1.7			LTL 0001112	LTL 0001113																																																												
	Ex. 1.8			LTL 0001114	LTL 0001115																																																												
	Ex. 1.9			LTL 0001116	LTL 0001119																																																												
	Ex. 1.10			LTL 0001120	LTL 0001134																																																												
	Ex. 1.11			LTL 0001135	LTL 0001144																																																												
	Ex. 1.12			LTL 0001145	LTL 0001146																																																												
	Ex. 1.13			LTL 0001147	LTL 0001150																																																												
	Ex. 1.14			LTL 0001151	LTL 0001158																																																												
	Ex. 1.15			LTL 0001159	LTL 0001176																																																												
	Ex. 1.16			LTL 0001177	LTL 0001191																																																												
	Ex. 1.17			LTL 0001192	LTL 0001204																																																												
	Ex. 1.18			LTL 0001205	LTL 0001221																																																												
	Ex. 1.19			LTL 0001222	LTL 0001234																																																												
	Ex. 1.20			LTL 0001235	LTL 0001254																																																												
Ex. 1.21	LTL 0001255	LTL 0001266																																																															

Ex.	Description			Beg. Bates No.	Confidential Designation
	Ex. 1.22	LTL 0001267	LTL 0001302		
	Ex. 1.23	LTL 0001303	LTL 0001326		
	Ex. 1.24	LTL 0001327	LTL 0001390		
	Ex. 1.25	LTL 0001391	LTL 0001817		
	Ex. 1.26	LTL 0001818	LTL 0001828		
	Ex. 1.27	LTL 0001829	LTL 0001831		
	Ex. 1.28	LTL 0001832	LTL 0001846		
	Ex. 1.29	LTL 0001847	LTL 0001849		
	Ex. 1.30	LTL 0001850	LTL 0001866		
	Ex. 1.31	LTL 0001867	LTL 0001873		
	Ex. 1.32	LTL 0001874	LTL 0001889		
	Ex. 1.33	LTL 0001890	LTL 0001900		
	Ex. 1.34	LTL 0001901	LTL 0001969		
	Ex. 1.35	LTL 0001970	LTL 0002036		
	Ex. 1.36	LTL 0002037	LTL 0002056		
	Ex. 1.37	LTL 0002057	LTL 0002098		
	Ex. 1.38	LTL 0002099	LTL 0002117		
	Ex. 1.39	LTL 0002118	LTL 0002131		
	Ex. 1.40	LTL 0002132	LTL 0002162		
	Ex. 1.41	LTL 0002163	LTL 0002173		
	Ex. 1.42	LTL 0002174	LTL 0002181		
	Ex. 1.43	LTL 0002182	LTL 0002185		
	Ex. 1.44	LTL 0002186	LTL 0002201		
	Ex. 1.45	LTL 0002202	LTL 0002215		
	Ex. 1.46	LTL 0002216	LTL 0002231		
	Ex. 1.47	LTL 0002232	LTL 0002245		
	Ex. 1.48	LTL 0002246	LTL 0002274		
	Ex. 1.49	LTL 0002275	LTL 0002278		
	Ex. 1.50	LTL 0002279	LTL 0002282		
	Ex. 1.51	LTL 0002283	LTL 0002299		

Ex.	Description			Beg. Bates No.	Confidential Designation
	Ex. 1.52	LTL 0002300	LTL 0002320		
	Ex. 1.53	LTL 0002321	LTL 0002327		
	Ex. 1.54	LTL 0002328	LTL 0002343		
	Ex. 1.55	LTL 0002344	LTL 0002357		
	Ex. 1.56	LTL 0002358	LTL 0002368		
	Ex. 1.57	LTL 0002369	LTL 0002380		
	Ex. 1.58	LTL 0002381	LTL 0002413		
	Ex. 1.59	LTL 0002414	LTL 0002445		
	Ex. 1.60	LTL 0002446	LTL 0002465		
	Ex. 1.61	LTL 0002466	LTL 0002476		
	Ex. 1.62	LTL 0002477	LTL 0002482		
	Ex. 1.63	LTL 0002483	LTL 0002486		
	Ex. 1.64	LTL 0002487	LTL 0002491		
	Ex. 1.65	LTL 0002492	LTL 0002508		
	Ex. 1.66	LTL 0002509	LTL 0002540		
	Ex. 1.67	LTL 0002541	LTL 0002571		
	Ex. 1.68	LTL 0002572	LTL 0002602		
	Ex. 1.69	LTL 0002603	LTL 0002631		
	Ex. 1.70	LTL 0002632	LTL 0002646		
	Ex. 1.71	LTL 0002647	LTL 0002662		
	Ex. 1.72	LTL 0002663	LTL 0002670		
	Ex. 1.73	LTL 0002671	LTL 0002687		
	Ex. 1.74	LTL 0002688	LTL 0002772		
	Ex. 1.75	LTL 0002773	LTL 0002791		
	Ex. 1.76	LTL 0002792	LTL 0002978		
	Ex. 1.77	LTL 0002979	LTL 0003012		
	Ex. 1.78	LTL 0003013	LTL 0003047		
	Ex. 1.79	LTL 0003048	LTL 0003066		
	Ex. 1.80	LTL 0003067	LTL 0003086		

Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 2	<i>In re LTL Management, LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Expert Report of Gregory K. Bell, Ph.D., offered January 28, 2022</li> </ul>		Confidential
MTD1 – Debtor’s Exhibit 3	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Expert Report of John R. Castellano, offered January 28, 2022</li> </ul>		Confidential
MTD1 – Debtor’s Exhibit 4	<i>In re LTL Management LLC</i> , No. 21-30589 (JCW), in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>Expert Report of Charles H. Mullin, Ph.D., offered October 29, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 5	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Debtor’s Responses and Objections to First Set of Interrogatories by the Official Committee of Talc Claimants in Connection with Motion to Dismiss, dated December 31, 2021</li> <li>Verification of John K. Kim in Support of Debtor’s Answers and Objections to First Set of Interrogatories of Official Committee of Talc Claimants, dated December 31, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 6	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Debtor’s Responses and Objections to First Set of Interrogatories by Arnold &amp; Itkin LLP in Connection with Motion to Dismiss, dated December 31, 2021</li> <li>Verification of John K. Kim in Support of Debtor’s Answers and Objections to First Set of Interrogatories of Arnold &amp; Itkin, dated December 31, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 7	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Debtor’s Amended Responses and Objections to Second Set of Interrogatories by Arnold &amp; Itkin LLP in Connection with Motion to Dismiss, dated January 27, 2022</li> </ul>		

Ex.	Description	Beg. Bates No.	Confidential Designation
	<ul style="list-style-type: none"> <li>Verification of John K. Kim in Support of Debtor's Amended Answers and Objections to Second Set of Interrogatories of Arnold &amp; Itkin, dated January 27, 2022</li> </ul>		
MTD1 – Debtor's Exhibit 8	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>January 19, 2022 Hearing Transcript</li> </ul>		
MTD1 – Debtor's Exhibit 9	October 14, 2021 American Association for Justice Statement on Johnson & Johnson's Declaration of Bankruptcy to Avoid Accountability for Dangerous Baby Powder		
MTD1 – Debtor's Exhibit 10	<i>In re LTL Management LLC</i> , No 21-30589, in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>Limited Omnibus Objection of the MDL Plaintiffs' Steering Committee to the Debtor's First Day Motions, filed October 19, 2021</li> </ul>		
MTD1 – Debtor's Exhibit 11	Beasley Allen article, "Ovarian Cancer Victims Vow Fight to Stop J&J's Bankruptcy Scheme"		
MTD1 – Debtor's Exhibit 12	<i>In re LTL Management LLC</i> , No. 21-30589, in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>October 20, 2021 First Day Hearing Transcript</li> </ul>		
MTD1 – Debtor's Exhibit 13	<i>In re LTL Management LLC</i> , No. 21-30589, in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>November 4, 2021 Hearing Transcript</li> </ul>		
MTD1 – Debtor's Exhibit 14	<i>In re LTL Management LLC</i> , No. 21-30589, in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>November 5, 2021 Hearing Transcript</li> </ul>		
MTD1 – Debtor's Exhibit 15	Johnson & Johnson Reconciliation of Non-GAAP Financial Measures, Fourth Quarter 2020		
MTD1 – Debtor's Exhibit 16	Johnson & Johnson Reconciliation of Non-GAAP Financial Measures, Fourth Quarter 2021		

Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 17	<i>In re LTL Management LLC</i> , No. 21-30589, in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>Informational Brief of LTL Management LLC</li> </ul>	LTL 0030038	
MTD1 – Debtor’s Exhibit 18	Minutes of the October 14, 2021 Meeting of the Board of Managers of LTL Management LLC	LTL 0019184	
MTD1 – Debtor’s Exhibit 19	Exhibit 14 to the deposition of Robert Wuesthoff, taken December 22, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK)	JNJ 000518810	
MTD1 – Debtor’s Exhibit 20	Exhibit 15 to the deposition of Robert Wuesthoff, taken December 22, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK)	JNJTALC0008 51887	
MTD1 – Debtor’s Exhibit 21	October 20, 2017 email to numerous individuals including Robert Wuesthoff with the subject line, “California Talc Verdict reversed”	JNJTALC0010 20384	
MTD1 – Debtor’s Exhibit 22	Exhibit 17 to the deposition of Robert Wuesthoff, taken December 22, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK)	JNJTALC0012 68780, JNJTALC0012 68782	
MTD1 – Debtor’s Exhibit 23	Exhibit 20 to the deposition of Robert Wuesthoff, taken December 22, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK)	JNJTALC0013 31402	
MTD1 – Debtor’s Exhibit 24	<i>Ingham v. Johnson &amp; Johnson</i> , 608 S.W.3d 663 (Mo. Ct. App. 2020), <i>reh’g and/or transfer denied</i> (July 28, 2020), <i>transfer denied</i> (Nov. 3, 2020), <i>cert. denied</i> , 141 S. Ct. 2716 (2021)		
MTD1 – Debtor’s Exhibit 25	<i>Johnson &amp; Johnson v. Ingham</i> , 141 S. Ct. 2716 (2021)		
MTD1 – Debtor’s Exhibit 26	<i>In re LTL Management LLC</i> , No. 21-30589 (JCW), in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division	LTL 0019833	

Ex.	Description	Beg. Bates No.	Confidential Designation
	<ul style="list-style-type: none"> <li>Exhibit 62, entitled, “Johnson &amp; Johnson Consumer Inc. Talc 2021 Accounting Entry Sample – Confidential”</li> </ul>		
MTD1 – Debtor’s Exhibit 27	Item 65 to Exhibit B of the Bell Expert Report, entitled “Johnson & Johnson Consumer Inc. balance sheet ending December 2017 (excluding branch income)”	LTL 0031551	Confidential
MTD1 – Debtor’s Exhibit 28	Item 66 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Consumer Inc. balance sheet ending December 2018 (excluding branch income)”	LTL 0031555	Confidential
MTD1 – Debtor’s Exhibit 29	Item 67 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Consumer Inc. balance sheet ending December 2019 (excluding branch income)”	LTL 0024246	
MTD1 – Debtor’s Exhibit 30	Item 68 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Consumer Inc. balance sheet ending December 2020 (excluding branch income)”	LTL 0024250	
MTD1 – Debtor’s Exhibit 31	Item 69 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Consumer Inc. balance sheet ending September 2021 (excluding branch income)”	LTL 0024253	
MTD1 – Debtor’s Exhibit 32	Item 70 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Consumer Inc. income statement for twelve months ended December 2018 (excluding branch income)”	LTL 0031557	Confidential
MTD1 – Debtor’s Exhibit 33	Item 71 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Consumer Inc. income statement for twelve months ended December 2019 (excluding branch income)”	LTL 0024248	
MTD1 – Debtor’s Exhibit 34	Item 72 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Consumer Inc. income statement for twelve months ended December 2020 (excluding branch income)”	LTL 0024251	
MTD1 – Debtor’s Exhibit 35	Item 73 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Consumer Inc. income statement for twelve months ended September 2021 (excluding branch income)”	LTL 0024254	



Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 36	Item 76 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Form 10-K for the fiscal year ended January 3, 2021”		
MTD1 – Debtor’s Exhibit 37	Item 77 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Form 10-K for the fiscal year ended December 29, 2019”		
MTD1 – Debtor’s Exhibit 38	Item 78 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Form 10-K for the fiscal year ended December 30, 2018”		
MTD1 – Debtor’s Exhibit 39	Item 79 to Exhibit B of the Bell Expert Report, entitled, “Johnson & Johnson Form 10-Q for the quarterly period ended October 3, 2021”		
MTD1 – Debtor’s Exhibit 40	PowerPoint presentation entitled, “Litigation and Product Liability Update,” dated October 13, 2021 with the subheading, “PwC Discussion”	LTL 0021775	Confidential
MTD1 – Debtor’s Exhibit 41	Item 118 to Exhibit B of the Bell Expert Report, entitled, “Financial Accounting Standards Board ASC 450-20-25”		
MTD1 – Debtor’s Exhibit 42	Item 131 to Exhibit B of the Bell Expert Report, entitled, “Talc Trial Results.DETAILED VERSION.xlsx”	LTL 0042900	Confidential
MTD1 – Debtor’s Exhibit 43	Item 158 to Exhibit B of the Bell Expert Report, entitled, “PL Talc-BP STS paid invoice spend from 2010-2021.xlsx”	LTL 0042980	Confidential
MTD1 – Debtor’s Exhibit 44	Item 132 to Exhibit B of the Bell Expert Report, entitled, “‘Talcum Powder,’ X Ante Mass Tort Intelligence, January 11, 2022”)	LTL 0042901	Confidential
MTD1 – Debtor’s Exhibit 45	Item 133 to Exhibit B of the Bell Expert Report, entitled, “2016 Talc Verdicts Impact on Enterprise Reputation.pptx.”	LTL 0042923	Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 46	Item 151 to Exhibit B of the Bell Expert Report, entitled, “Five Days in December_v2.pptx, January 2019”	LTL 0042926	Confidential
MTD1 – Debtor’s Exhibit 47	Item 152 to Exhibit B of the Bell Expert Report, entitled, “JJ Corporate Reputation update (Sneed) BoD Update, Nov 2016.pptx, November 2016”	LTL 042953	Confidential
MTD1 – Debtor’s Exhibit 48	Item 153 to Exhibit B of the Bell Expert Report, entitled, “JJ Reputation – EMEA & Policy Elites 03.23.2016.pptx, March 23, 2016”	LTL 0042965	Confidential
MTD1 – Debtor’s Exhibit 49	Item 159 to Exhibit B of the Bell Expert Report, entitled, “WW Government Affairs and Policy YE 2018 Briefing 01.2019 vf.pptx, January 29, 2019”	LTL 0042981	Confidential
MTD1 – Debtor’s Exhibit 50	Item 3 to Exhibit B of the Bell Expert Report, entitled “ <i>In re Imerys Talc America, Inc. et al.</i> , In the United States Bankruptcy Court for the District of Delaware, Case No. 19-10289 (LSS), Tenth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates, September 16, 2021” (“Imerys Tenth Amended Plan”), § 3.3		
MTD1 – Debtor’s Exhibit 51	Item 4 to Exhibit B of the Bell Expert Report, entitled, “ <i>In re Imerys Talc America, Inc. et al.</i> , In the United States Bankruptcy Court for the District of Delaware, Chapter 11 Case No. 19-10289 (LSS), Ninth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code, dated January 28, 2021”		
MTD1 – Debtor’s Exhibit 52	Item 5 to Exhibit B of the Bell Expert Report, entitled, “ <i>In re Imerys Talc America, Inc. et al.</i> , In the United States Bankruptcy Court for the District of Delaware, Chapter 11 Case No. 19-10289 (LSS), Order (I) Approving Sale of Substantially All of the Debtors’ Assets Free and Clear of Liens, Claims, Encumbrances, and other Interests, (II) Authorizing Assumption and Assignment of Certain Executory Contracts and Unexpired Leases in Connection Therewith and (III) Granting Related Relief, dated November 17, 2020”		

Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 53	Item 11 to Exhibit B of the Bell Expert Report, entitled, “Trust Distribution procedures, January 28, 2021”		
MTD1 – Debtor’s Exhibit 54	Item 12 to Exhibit B of the Bell Expert Victoria Lynn Giese, Angela Trentmann, and Susan Vogeler, Plaintiffs, v. Johnson & Johnson and Johnson & Johnson Consumer Inc., Missouri Circuit Court Twenty-Second Judicial Circuit (City of St. Louis) <ul style="list-style-type: none"> <li>Petition in Equity, dated August 24, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 55	Exhibit 107 to the deposition of Michelle Ryan, taken January 27, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK)	LTL 0030191	
MTD1 – Debtor’s Exhibit 56	Project Plato Memorandum of Approval, sent on and dated October 11, 2021	LTL 0030294	
MTD1 – Debtor’s Exhibit 57	Michelle Ryan’s Consent to the Project Plato Memorandum of Approval, emailed October 11, 2021	LTL 0030223	
MTD1 – Debtor’s Exhibit 58	Valuation of Old JJCI	LTL 0030450	Confidential
MTD1 – Debtor’s Exhibit 59	Exhibit 34 to the deposition of Thibaut Mongon, taken January 19, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), entitled, “Johnson & Johnson’s (JNJ) Management Presents at Barclays Global Consumer Staples Conference (Transcript),” dated September 10, 2021		
MTD1 – Debtor’s Exhibit 60	Exhibit 39 to the deposition of Thibaut Mongon, taken January 19, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), entitled, “Johnson & Johnson (JNJ) Q3 2021 Results – Earnings Call Transcript,” dated October 19, 2021		
MTD1 – Debtor’s Exhibit 61	February 23, 2016 Email from D. Bass to J. Mesquita et al. re: “URGENT: Talc Update”	JNJTALC0013 80169	

Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 62	October 28, 2016 Email from T. Mongon to Consumer AP Employees et al. re: “Talc Update”	JNJ000800251	
MTD1 – Debtor’s Exhibit 63	December 4, 2019 Email from K. Wengel to JJCUS Enterprise Supply Chain Leadership Team re: “Bernstein Analyst Report for Investor Visit to Consumer Skillman R&D Site,” and attachment	JNJTALC0013 21834 & JNJTALC0013 21838	
MTD1 – Debtor’s Exhibit 64	Exhibit 31 to the deposition of Thibaut Mongon, taken January 19, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), a January 31, 2020 Email from D. Lorensen to M. Sneed et al. re: “INFORM: Talc News next week”	JNJTALC0014 58089	
MTD1 – Debtor’s Exhibit 65	May 7, 2020 Email from K. Widmer to T. Mongon re: “Talc Reco,” and attachments	JNJTALC0014 36789, JNJTALC0014 36790, & JNJTALC0014 36791	
MTD1 – Debtor’s Exhibit 66	U.S. Chamber Institute for Legal Reform, “Gaming the System: How Lawsuit Advertising Drives the Litigation Lifecycle,” dated April 2020	JNJTALC0014 36791	
MTD1 – Debtor’s Exhibit 67	Exhibit 26 to the deposition of Thibaut Mongon, taken January 19, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), entitled, “Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business,” dated November 12, 2021		
MTD1 – Debtor’s Exhibit 68	Exhibit 44 to the deposition of Thibaut Mongon, taken January 19, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), an October 11, 2021 Email from C. Andrew to T. Mongon re: “Project Plato Approval Memorandum for Approval Today”	LTL 0031330	
MTD1 – Debtor’s Exhibit 69	Exhibit 9 to the deposition of Thibaut Mongon, taken January 19, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), an October 11, 2021 Approval Request for the Restructuring of Johnson & Johnson Consumer Inc.	LTL 0021791	

Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 70	Exhibit 36 to the deposition of Thibaut Mongon, taken January 19, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), an October 11, 2021 Email from C. Andrew to T. Mongon re: “Project Plato Approval Memorandum for Approval Today”	LTL 0031328	
MTD1 – Debtor’s Exhibit 71	Exhibit 14 to the deposition of Robert Wuesthoff, taken December 22, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), a May 3, 2016 Email from J. Ghaim to T. Glasgow re: “Talc Update”	JNJ 000518810	
MTD1 – Debtor’s Exhibit 72	Exhibit 15 to the deposition of Robert Wuesthoff, taken December 22, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), a July 19, 2016 Email from J. James to A. Nwaneri re: “New Talc Website Launched”	JNJTALC0008 51887	
MTD1 – Debtor’s Exhibit 73	October 21, 2017 Email from M. Saitzyk to C. Goodrich and A. Scavazzini re: “California Talc Verdict Reversed”	JNJTALC0010 20384	
MTD1 – Debtor’s Exhibit 74	Exhibit 17 to the deposition of Robert Wuesthoff, taken December 22, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), a December 15, 2018 Email from D. Lorensen to J. Mesquita et al. re: “Update on talc”	JNJTALC0012 68780, JNJTALC0012 68782	
MTD1 – Debtor’s Exhibit 75	Exhibit 20 to the deposition of Robert Wuesthoff, taken December 22, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), a December 3, 2019 Email from S. Macdonald to D. Jodrey et al. re: “Reuters article on talc in news today”	JNJTALC0013 31402	
MTD1 – Debtor’s Exhibit 76	2021-12-08 Second Supplemental Declaration of John K. Kim in Support of Debtor’s Supplemental Memorandum of Law in Support of the Preliminary Injunction Motion, filed in <i>In re LTL Management LLC</i> , No. 21-30589 (MBK) and Exhibits A – P cited therein		
MTD1 – Debtor’s Exhibit 77	2022-01-05 Third Supplemental Declaration of John K. Kim in Support of Debtor’s Omnibus Reply in Support of the Preliminary Injunction Motion, filed in <i>In re LTL Management LLC</i> , No. 21-30589 (MBK) and Exhibits A – U cited therein		
MTD1 – Debtor’s Exhibit 78	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Expert Report of Matthew Diaz, offered January 28, 2022</li> </ul>		

Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 79	January 6, 2020 PowerPoint presentation entitled, “Paddock Enterprises, LLC (An O-I Glass, Inc. Affiliate) Seeks A Final And Equitable Resolution To Its Legacy Asbestos-Related Claims”		
MTD1 – Debtor’s Exhibit 80	April 26, 2021 O-I press release entitled, “O-I Glass Announces Agreement of Potential Plan of Reorganization for Paddock Subsidiary”		
MTD1 – Debtor’s Exhibit 81	<i>In re Paddock Enterprises, LLC</i> , No. 20-03041, in the United States Bankruptcy Court for the District of Delaware <ul style="list-style-type: none"> <li>Declaration of David J. Gordon, President and Chief Restructuring Officer of the Debtor, in Support of Chapter 11 Petition and First Day Pleadings, filed April 23, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 82	<i>In re Garlock Sealing Technologies LLC, et al.</i> , No. 10-BK-31607, in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>Disclosure Statement for Modified Joint Plan of Reorganization of Garlock Sealing Technologies LLC, et al. and Oldco, LLC, Proposed Successor by Merger to Coltec Industries Inc, filed July 29, 2016</li> </ul>		
MTD1 – Debtor’s Exhibit 83	October 12, 2021 document entitled, “Amended and Restated Funding Agreement,” between Johnson & Johnson, Johnson & Johnson Consumer Inc., and LTL Management LLC	LTL 0000001	
MTD1 – Debtor’s Exhibit 84	<i>In re Aldrich Pump LLC, et al.</i> , No. 20-30608 (JCW), in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>Expert Report of Matthew Diaz, dated February 12, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 85	<i>In re DBMP LLC</i> , No. 20-30080 (JCW), in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>Expert Report of Matthew Diaz, dated October 20, 2020</li> </ul>		
MTD1 – Debtor’s Exhibit 86	Exhibit 10 to the deposition of Michelle Goodridge, taken December 20, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), a May 19, 2020 Email from K. Wallace to L. Deo et al. re: “CONFIDENTIAL: Final Materials for Today”	JNJALC0014 36896	

Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 87	Oasis Financial website post entitled, “10 of the Largest Personal Injury Verdicts & Settlements in History”		
MTD1 – Debtor’s Exhibit 88	<i>In re LTL Management LLC</i> , No. 21-30589, in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>Supplemental Declaration of John K. Kim in Support of Debtor’s Complaint for Declaratory and Injunctive Relief and Related Motions, filed October 21, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 89	<i>In re LTL Management, LLC</i> , No. 21-03032 (JCW), in the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division <ul style="list-style-type: none"> <li>Declaration of John K. Kim in Support of First Day Pleadings, filed October 14, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 90	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Debtor’s Objection to Motions to Dismiss Chapter 11 Case, filed December 22, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 91	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Request for Judicial Notice, filed by the Official Committee of Talc Claimants II on February 8, 2022</li> </ul>		
MTD1 – Debtor’s Exhibit 92	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Canadian Class Action Plaintiffs’ Opposition to Motions to Dismiss Chapter 11 Case, filed February 8, 2022</li> </ul>		
MTD1 – Debtor’s Exhibit 93	<i>Lee v. A.W. Chesterton Company</i> , No. FCS050176, in the Superior Court of the State of California in and for the County of Solano <ul style="list-style-type: none"> <li>Transcript of the Deposition of John Hopkins, PH.D., taken February 7, 2019</li> </ul>		
MTD1 – Debtor’s Exhibit 94	<i>Ingham v. Johnson &amp; Johnson</i> , No. 1522-CC10417-01, in the Circuit Court of the City of St. Louis, State of Missouri <ul style="list-style-type: none"> <li>Trial Transcript from June 14, 2018</li> </ul>		



Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 95	<i>Giese v. Johnson &amp; Johnson</i> , Case No. 1522-CC0041902, in the Circuit Court of the City of St. Louis, State of Missouri <ul style="list-style-type: none"> <li>Trial Transcript from Monday, September 27, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 96	<i>Forrest v. Johnson &amp; Johnson</i> , No. 1522-CC00419-02, in the Circuit Court of the City of St. Louis, State of Missouri <ul style="list-style-type: none"> <li>Trial Transcript, Volume 15B, from December 20, 2019</li> </ul>		
MTD1 – Debtor’s Exhibit 97	<i>Johnson v. Johnson &amp; Johnson</i> , No. JCCP 4674/20STCV17335, in the Superior Court of the State of California for the County of Los Angeles <ul style="list-style-type: none"> <li>Trial Transcript, Wednesday, October 6, 2021</li> </ul>		
MTD1 – Debtor’s Exhibit 98	Publication entitled, “Financial Accounting Standards Board, Statement of Financial Accounting Concepts No. 5,” dated December 1984		
MTD1 – Debtor’s Exhibit 99	Publication entitled, “Financial Accounting Standards Board, Statement of Financial Accounting Concepts No. 6,” dated December 1985		
MTD1 – Debtor’s Exhibit 100	Exhibit 234 to the deposition of Adam Lisman, taken February 8, 2021 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), Johnson & Johnson Consumer Inc. Balance Sheet for the period ending September 2021	LTL 0024253	
MTD1 – Debtor’s Exhibit 101	Exhibit 235 to the deposition of Adam Lisman, taken February 8, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), Johnson & Johnson Consumer Inc. Income Statement for the period ending September 2021	LTL 0024254	
MTD1 – Debtor’s Exhibit 102	Exhibit 284 to the deposition of Adam Lisman, taken February 8, 2022 in the matter of <i>In re LTL Management LLC</i> , No. 21-30589 (MBK), a document entitled, “Worldwide Financial Procedures, 330Ba – Legal Fees”	LTL 0021763	
MTD1 – Debtor’s Exhibit 103	Publication entitled, “Financial Accounting Standards Board Conceptual Framework, Statement of Financial Accounting Concepts No. 8, Conceptual Framework for Financial Reporting, Chapter 4, <i>Elements of Financial Statements</i> ,” dated December 2021		



Ex.	Description	Beg. Bates No.	Confidential Designation
MTD1 – Debtor’s Exhibit 104	<i>In re LTL Management LLC</i> , No. 21-30589 (MBK), in the United States Bankruptcy Court for the District of New Jersey <ul style="list-style-type: none"> <li>Expert Report of Saul E. Burian, dated January 28, 2022</li> </ul>		
MTD1 – Debtor’s Exhibit 105	Transcript of the deposition of Thibaut Mongon, taken January 19, 2022, in <i>In re LTL Management LLC</i> , No. 21-30589 (MBK)		
MTD1 – Debtor’s Exhibit 106	<i>In re Bestwall LLC</i> , 605 B.R. 43 (Bankr. W.D.N.C. 2019) (Bestwall Dismissal Opinion)		
MTD1 – Debtor’s Exhibit 107	Royalty A&M DCF Analysis	LTL 0029874	Confidential
MTD1 – Debtor’s Exhibit 108	April 30, 2019 Email from P. Kwan to D. Kaplan re: “Talc”	SPGI0000080	Confidential
MTD1 – Debtor’s Exhibit 109	Praedicat Inc. article entitled, “Talc: the next wave of asbestos litigation?”	SPGI0000081	Confidential
MTD1 – Debtor’s Exhibit 110	The Unpredictable Cost of Latent Catastrophes, Patricia Kwan		
MTD1 – Debtor’s	Johnson & Johnson Form 10-K for the fiscal year ended January 3, 2021	LTL 0029717	

Ex.	Description	Beg. Bates No.	Confidential Designation
Exhibit 111			
<b>Exhibits from the Preliminary Injunction Hearing for LTL 1</b>			
PI 1 Exhibit 1	2021 Corporate Restructuring documents, closing binder and all documents therein	LTL 0001058-LTL 0003086	
PI 1 Exhibit 2	Agreement for Transfer of Assets and Bill of Sale, dated January 1, 1979, between Johnson & Johnson and Johnson & Johnson Baby Products Company	LTL 000557	
PI 1 Exhibit 3	Agreement for Transfer of Assets and Bill of Sale, dated January 1, 1979, between Johnson & Johnson and Johnson & Johnson Baby Products Company	LTL 000565	
PI 1 Exhibit 4	Funding Agreement between Johnson & Johnson, Johnson & Johnson Consumer Inc., and LTL Management LLC, dated October 12, 2021	LTL 0002300	
PI 1 Exhibit 5	Merger Support Agreement Johnson & Johnson Consumer Inc., and LTL Management LLC, dated October 12, 2021	LTL 0002321	
PI 1 Exhibit 6	December 12, 1978 Board of Directors Meeting Minutes	LTL 0000021	
PI 1 Exhibit 7	LTL Management LLC's Minutes of Board of Managers and Resolutions, dated October 14, 2021	LTL 0019184	
PI 1 Exhibit 8	FRE 1006 Insurance Coverage Evidence Summary	LTL 0023515	
PI 1 Exhibit 9	Johnson & Johnson Insurance Coverage Chart	LTL 0003087	
PI 1 Exhibit 10	Insurance Agreement: Aetna #38 AL 12880 SR(Y)_1-1-1967 to 1-1-1970	LTL 0000168	
PI 1 Exhibit 11	Insurance Agreement: Aetna 38 XN 07 SCA	LTL 0000317	
PI 1 Exhibit 12	Insurance Agreement: Home HEC 4764031	LTL 0000387	
PI 1 Exhibit 13	Insurance Agreement: North River JU 0802	LTL 0000410	
PI 1 Exhibit 14	Insurance Agreement: Aetna Primary 38 PK 15 SCA	LTL 0000511	

Ex.	Description	Beg. Bates No.	Confidential Designation
PI 1 Exhibit 15	1989 Agreement with Safeway for indemnification	LTL 0019160	
PI 1 Exhibit 16	2020 Agreement with HEB for indemnification	LTL 0022538	
PI 1 Exhibit 17	FRE 1006 Tender Agreement Evidence Summary	LTL 0023527	
PI 1 Exhibit 18	Tender Agreement wherein Johnson & Johnson Consumer Inc. agrees to tender defense and indemnify Safeway for claims by Abbott, Richard, dated May 13, 2019	LTL 0012853	
PI 1 Exhibit 19	Tender Agreement wherein Johnson & Johnson Consumer Inc. agrees to tender defense and indemnify Albertson for claims by Lane, Ardys, dated October 8, 2018	LTL 0013141	
PI 1 Exhibit 20	MDL Second Amended Master Complaint, MDL NO. 16-2738 (D.N.J. Dec. 22, 2020)	LTL 0012521	
PI 1 Exhibit 21	<i>Cadagin, et al v. Johnson &amp; Johnson, et al.</i> , No. 18-L-572 In the Circuit Court of the Twentieth Judicial Circuit St. Clair County, Illinois, <ul style="list-style-type: none"> <li>Jul. 28, 2021 Trial Transcript</li> <li>Verdict form</li> </ul>	LTL 0018560 LTL 0018713	
PI 1 Exhibit 22	<i>Anderson et al. v. Borg Warner Corp. et al.</i> , No. BC666513, in the Superior Court for the State of California, County of Los Angeles (Jun. 27, 2017)	LTL 0017642	
PI 1 Exhibit 23	<i>Barden v. Johnson &amp; Johnson, et al.</i> , MID-L-1809-17AS, Superior Court of New Jersey, Middlesex County <ul style="list-style-type: none"> <li>Feb. 6, 2021 Trial Transcript</li> </ul>	LTL 0017692	
PI 1 Exhibit 24	<i>Prudencio v. Johnson &amp; Johnson</i> , No. RG20061303, in the Superior Court of California, Alameda County <ul style="list-style-type: none"> <li>Aug. 13, 2021 Trial Transcript</li> </ul>	LTL 0017980	
PI 1 Exhibit 25	<i>Vanklive v. Johnson &amp; Johnson</i> , No. RC20062734, Superior Court of California, County of Alameda <ul style="list-style-type: none"> <li>Oct. 22, 2021 Trial Transcript</li> </ul>	LTL 0018460 LTL 0018473	

Ex.	Description	Beg. Bates No.	Confidential Designation
	<ul style="list-style-type: none"> <li>Oct. 26, 2021 Trial Transcript</li> </ul>		
PI 1 Exhibit 26	<i>McBride et al. v American International Industries, Inc., et al.</i> , No. 49D13-2110-MI-034781, Marion County Superior Court for the State of Indiana (Oct. 15, 2021)	LTL 0018439	
PI 1 Exhibit 27	<i>McBrayer, et al. v. Acme et al.</i> , No. 2020-CP10-03946, County of Charleston for the State of South Carolina <ul style="list-style-type: none"> <li>October 28, 2021 Trial Transcript</li> </ul>	LTL 0021919	
PI 1 Exhibit 28	Transcript of July 30, 2019 proceeding in <i>Hayes v. Colgate Palmolive Co.</i> , Case No. 16-CI-03503 (Ky. Cir. Ct. Jefferson Jul. 30, 2019), Testimony of Dr. John Hopkins	LTL 0022023	
PI 1 Exhibit 29	Settlement Facility Agreement by and among Johnson & Johnson, Johnson & Johnson Consumer Inc., LTL Management LLC, and U.S. Bank National Association, as the Trustee, Funding Agreement Documents	Dkt. 8 – 1, Ex. A	
PI 1 Exhibit 30	Reliance materials of expert Charles H. Mullin PhD	LTL 0021298- LTL 0021762	
PI 1 Exhibit 31	Expert report of Charles H. Mullin PhD		
PI 1 Exhibit 32	List of Protected Parties	Adv. Pro. Dkt. 1 -1, Appendix B; Adv. Pro. Dkt. 2-1, Appendix B	
PI 1 Exhibit 33	Agreement between Cyprus Mines Corporation and Johnson & Johnson, dated Jan. 6, 1989	LTL 0023277	
PI 1 Exhibit 34	Plan and Agreement of Reorganization between Eastern Magnesia Talc Co., Inc., and Johnson & Johnson, dated July 30, 1965.	LTL 0023255	
PI 1 Exhibit 35	Acquisition of the assets and Liabilities of Eastern Magnesia Talc Co., Inc. by a Wholly-Owned Subsidiary of Johnson & Johnson, dated July 30, 1965	LTL 0023253	
PI 1 Exhibit 36	Asset Purchase Agreement between Johnson & Johnson Consumer Companies, Inc. and Pharma Teach Industries, Inc., dated Apr. 4, 2005 – Confidential	LTL 0000610	

Ex.	Description	Beg. Bates No.	Confidential Designation
PI 1 Exhibit 37	Manufacturing and Supply Agreement between Johnson & Johnson Consumer Companies, Inc. and Pharma Teach Industries, Inc., dated Aug. 29, 2005 – Confidential	LTL 0000736	
PI 1 Exhibit 38	2008 Amendment to Manufacturing and Supply Agreement between Johnson & Johnson Consumer Companies, Inc. and Pharma Teach Industries, Inc., dated Aug. 29, 2005 – Confidential	LTL 0000811	
PI 1 Exhibit 39	2013 Amendment to Manufacturing and Supply Agreement between Johnson & Johnson Consumer Companies, Inc. and PTI Royston, LLC, dated Aug. 29, 2005 – Confidential	LTL 0000817	
PI 1 Exhibit 40	2017 Amended and Restated Supply Agreement between Johnson & Johnson Consumer Companies, Inc. and PTI Royston, LLC, dated Aug. 29, 2005 – Confidential	LTL 0000842	
PI 1 Exhibit 41	Indemnification agreement between Bausch Health Companies (f/k/a Valeant Pharmaceuticals International, Inc.) and Johnson & Johnson Consumer, Inc., dated Sept. 9, 2012	LTL 0001050	
PI 1 Exhibit 42	2020 Johnson & Johnson Annual Report	LTL 0017485	
PI 1 Exhibit 43	Johnson & Johnson Medical Safety Counsel Charter, dated April 19, 2013	LTL 0021817	
PI 1 Exhibit 44	Johnson & Johnson Medical Safety Counsel Charter, dated April 10, 2014	LTL 0021827	
PI 1 Exhibit 45	Johnson & Johnson Medical Safety Counsel Charter, dated July 27, 2015	LTL 0021838	
PI 1 Exhibit 46	Consumer Medical Safety Counsel Operational Charter, dated June 26, 2017	LTL 0021848	
PI 1 Exhibit 47	Consumer Medical Safety Counsel Operational Charter, dated June 28, 2018	LTL 0021859	
PI 1 Exhibit 48	Consumer Medical Safety Counsel Operational Charter, dated March 6, 2019	LTL 0021870	
PI 1 Exhibit 49	Declaration of Susan Schirger-Ward	N/A	

Ex.	Description	Beg. Bates No.	Confidential Designation
PI 1 Exhibit 50	Declaration of Adam Lisman	N/A	
PI 1 Exhibit 51	Letter from A.J. Huetteman to A. Marinaro, dated October 31, 1977	LTL 0012488	
PI 1 Exhibit 52	Johnson & Johnson Baby Products Company Action Authorized by Unanimous Consent of Shareholder, dated July 21, 1981, attaching Agreement for Transfer of Assets and Bill of Sale, dated July 27, 1981, between Johnson & Johnson Baby Products Company and Omni Education Corporation	LTL 0012489	
PI 1 Exhibit 53	Certificate of Merger of Personal Products Company into Johnson & Johnson Baby Products Company, dated July 27, 1981	LTL 0012497	
PI 1 Exhibit 54	Agreement for Transfer of Assets and Bill of Sale, dated January 3, 1988, between Johnson & Johnson Baby Products Company (renamed Johnson & Johnson Orthopaedics) and Johnson & Johnson Dental Products (renamed Johnson & Johnson Consumer Products, Inc.)	LTL 0012508	
PI 1 Exhibit 55	Johnson & Johnson Consumer Companies, Inc. Certificate of Incorporation, dated July, 1, 1997	LTL 0012513	
PI 1 Exhibit 56	Incorporation of Personal Products, dated October 9, 1970	LTL 0019433	
PI 1 Exhibit 57	Certificate of Merger between McNeil Consumer Products Company and Personal Products Company, dated November 28, 1988	LTL 0019498	
PI 1 Exhibit 58	Certificate of Merger, dated June 25, 2015, between Neutrogena, LLC, Johnson & Johnson Consumer Companies LLC, Johnson & Johnson Sales and Logistics Company, LLC, and McNEIL-PPC, Inc.	LTL 0019427	
PI 1 Exhibit 59	Certificate of Merger between Johnson & Johnson Consumer Companies, LLC and Johnson & Johnson Consumer Companies, Inc., dated June 25, 2015	LTL 0012706	
PI 1 Exhibit 60	Asset Purchase Agreement among Johnson & Johnson Consumer Companies, Inc. and Valeant Pharmaceuticals International, Inc., dated September 9, 2012	LTL 0000954	
PI 1 Exhibit 61	Agreement and Plan of Merger dated, dated June 25, 2015, between Neutrogena, LLC, Johnson & Johnson Consumer Companies LLC, Johnson & Johnson Sales and Logistics Company, LLC, and McNEIL-PPC, Inc.	LTL 0012710	

Ex.	Description	Beg. Bates No.	Confidential Designation
PI 1 Exhibit 62	Johnson & Johnson Consumer Inc. Talc 2021 Accounting Entry Sample – Confidential	LTL 0019833	
PI 1 Exhibit 63	Talc 2007-2021 Other Income & Expense Details – Confidential	LTL 0019178	
PI 1 Exhibit 64	Johnson & Johnson Worldwide Financial Procedures, 330Ba - Legal Fees, last revised March 2005	LTL 0021763	
PI 1 Exhibit 65	Johnson & Johnson 10-K, dated January 2, 1977	LTL 0023352	
PI 1 Exhibit 66	Johnson & Johnson 10-K, dated December 30, 1979	LTL 0023395	
PI 1 Exhibit 67	1986 Johnson & Johnson Annual Report	LTL 0023445	
PI 1 Exhibit 68	Johnson & Johnson 10-K, dated January 1, 1978	LTL 0019191	
PI 1 Exhibit 69	Johnson & Johnson 10-K, dated December 31, 1978	LTL 0019235	
PI 1 Exhibit 70	Excerpt from 1985 Annual Report	LTL 0019296	
PI 1 Exhibit 71	Excerpt from 1986 Annual Report	LTL 0019297	
PI 1 Exhibit 72	Excerpt from 1989 Annual Report	LTL 0019298	
PI 1 Exhibit 73	Agreement between Johnson & Johnson Consumer Companies, Inc. and PTI Royston, LCC regarding Talc Sanitization Project, dated March 15, 2011	LTL 0019380	
PI 1 Exhibit 74	Asset Purchase Agreement between Johnson & Johnson Consumer Companies, Inc. and Valeant Pharmaceuticals International, Inc., dated Sept. 9, 2012	LTL 0019502	
PI 1 Exhibit 75	Disclosure Schedule to Asset Purchase Agreement between Johnson & Johnson Consumer Companies, Inc. and Valeant Pharmaceuticals International, Inc., dated Sept. 9, 2012	LTL 0019598	
PI 1 Exhibit 76	Executive Committee Actions, Dated July 18 to September 11, 1986	LTL 0019687	

Ex.	Description	Beg. Bates No.	Confidential Designation
PI 1 Exhibit 77	Figure 1 from the Expert Report of Dr. Charles Mullin of October 29, 2021		
PI 1 Exhibit 78	Figure 2 from the Expert Report of Dr. Charles Mullin of October 29, 2021		
PI 1 Exhibit 79	Figure 3 from the Expert Report of Dr. Charles Mullin of October 29, 2021		
PI 1 Exhibit 80	Trial outcome chart	LTL 0023514	
PI 1 Exhibit 81	Johnson & Johnson Medical Safety Standard	LTL 0023609	
<b>Exhibits for the Preliminary Injunction Hearing for LTL 2</b>			
PI 2 Exhibit 1	Declaration of John K. Kim in Support of First Day Pleadings, Case No. 23-12825 (“Kim Decl.”), including all exhibits thereto:	LTLMGMT-00000020	
	Annex A to Kim Decl., 1979 Agreement		
	Annex B to Kim Decl., Debtor’s Corporate Structure Chart		
	Annex C to Kim Decl., Form Plan Support Agreement		
	Annex D to Kim Decl., Termination and Substitution Agreement		
	Annex E to Kim Decl., 2023 Funding Agreement		
	Annex F to Kim Decl., J&J Support Agreement		
	Annex G to Kim Decl., March 6, 2023 Letter from Trailblazers		
	Annex H to Kim Decl., March 21, 2023 Letter from Trailblazers’ Counsel		
	Annex I to Kim Decl., Plaintiff’s Response to Defendants’ Opposition to Trailblazer Studios’ Request to Record Trial Proceedings		
PI 2 Exhibit 19	Term Sheet – HIGHLY CONFIDENTIAL	LTLMGMT-00002628	Highly Confidential
PI 2 Exhibit 20	Minutes of Board of Managers LTL Management LLC (March 16, 2023)	LTLMGMT-00002626	Confidential
PI 2 Exhibit 21	Minutes of Board of Managers LTL Management LLC (March 28, 2023)	LTLMGMT-00000001	Confidential



Ex.	Description	Beg. Bates No.	Confidential Designation
PI 2 Exhibit 22	Minutes of Board of Managers LTL Management LLC (April 2, 2023)	LTLMGMT-00000006	Confidential
PI 2 Exhibit 23	Presentation to Board of Managers of LTL Management LLC (March 28, 2023)	LTLMGMT-00002641	Confidential
PI 2 Exhibit 24	Presentation to Board of Managers of LTL Management LLC (April 2, 2023)	LTLMGMT-00002668	Confidential
PI 2 Exhibit 25	Template non-executed NDA	LTLMGMT-00002680	Confidential
PI 2 Exhibit 26	2022 Group Holdings	LTLMGMT-00000192	Confidential
PI 2 Exhibit 27	Johnson & Johnson Holdco (NA) Inc. (US -6101) ("Old JJCI") Structure Chart	LTLMGMT-00000194	Confidential
PI 2 Exhibit 28	Emory Hernandez Facebook Profile		
PI 2 Exhibit 29	Emory Hernandez Facebook Post (Feb. 27, 2023)		
PI 2 Exhibit 30	Plaintiff's Notices of Deposition for Person(s) Most Qualified, Reyes (July 15, 2020)		
PI 2 Exhibit 31	Plaintiff's Notices of Deposition for Person(s) Most Qualified, Vanklive (Nov. 24, 2020)		
PI 2 Exhibit 32	Plaintiff's Notices of Deposition for Person(s) Most Qualified, Prudencio (Dec. 8, 2020)		
PI 2 Exhibit 33	2022.02.04 Stanford Adv. Med. Center Roy Thoracic Oncology f-u		Confidential
PI 2 Exhibit 34	2022.02.11 Stanford Adv. Med. Center Telephone Encounters re High Heart Rate, ED Referral		Confidential
PI 2 Exhibit 35	2022.03.04 Stanford Adv. Med Center Roy Diagnosis of Pericardium Primary Mesothelioma		Confidential
PI 2 Exhibit 36	2022.03.18 Stanford Adv. Med Center Roy Progress Notes & Infusion Reaction		Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
PI 2 Exhibit 37	2022.04.09 - 2022.04.10 Stanford Hospital Antineoplastic Chemotherapy		Confidential
PI 2 Exhibit 38	2022.08.03 Stanford Tooth Pain Phone Call, Rescheduling, Med Refill Reports		Confidential
PI 2 Exhibit 39	2022.08.08 Stanford Cancer Genetics, Treatment, Med Refill Reports		Confidential
PI 2 Exhibit 40	Transcript of Deposition of Barry R. Horn, M.D., <i>Valadez v. Johnson &amp; Johnson et al.</i> , No. 22-cv-012759, Alameda County Superior Court (Mar. 27, 2023)		
PI 2 Exhibit 41	Transcript of Deposition of Annamarie Camacho, <i>Valadez v. Johnson &amp; Johnson et al.</i> , No. 22-cv-012759, Alameda County Superior Court (Mar. 2, 2023)		
PI 2 Exhibit 42	Valadez - Plaintiff's Letter to ACOR re Dodson Materials (Dodson Reports), sent 2/28/2023		
PI 2 Exhibit 43	Declaration of Ronald F. Dodson, <i>In re LTL Management LLC</i> , 21-30589 (MBK), filed 5/24/022		
PI 2 Exhibit 44	Valadez Deposition Exhibit 4, photo of bottles		
PI 2 Exhibit 45	Weaver & Long article entitled, "Chromogenic Characterization: A Study of Kodak Color Prints, 1942-2008"		
PI 2 Exhibit 46	Email from Rivamonte to Roy, with attachments, dated 9/20/2022		
PI 2 Exhibit 47	U.S. Census Bureau QuickFacts		
PI 2 Exhibit 48	Plaintiff's Opposition to Joint Defendant Johnson & Johnson's Motion in Limine No. 2 to Exclude References to LTL Management LLC's Bankruptcy, filed 4/3/2023, <i>Valadez v. Johnson &amp; Johnson et al.</i> , No. 22-cv-012759, Alameda County Superior Court		
PI 2 Exhibit 49	Plaintiff's Notice of Deposition of Defendant Johnson & Johnson's Custodian(s) or Records and Person(s) Most Qualified, filed 3/7/2023, <i>Valadez v. Johnson &amp; Johnson et al.</i> , No. 22-cv-012759, Alameda County Superior Court		
PI 2 Exhibit 50	Federica Grosso article entitled, "Pericardial Mesothelioma, a Disease for Brave Hearts"		

Ex.	Description	Beg. Bates No.	Confidential Designation
PI 2 Exhibit 51	Email from Satterley to Brown re: LTL Stay, dated 4/4/2023		
PI 2 Exhibit 52	Letter from Kazan, McClain, Satterley & Greenwood objecting to genetic testing, dated 3/14/2023		
PI 2 Exhibit 53	Birchfield Deposition Exhibit 003 – Beasley Allen Press Release entitled, “Cancer Victims Uniting to Oppose Johnson & Johnson’s Latest Bankruptcy Ploy”		
PI 2 Exhibit 54	Murdica Deposition Exhibit 6 – Reuters Article entitled, “J&J talc unit 2nd bankruptcy must be dismissed, cancer victims’ lawyers say”		
PI 2 Exhibit 55	Watts Deposition Exhibit 3 – Watts Guerra LLC Press Release entitled, “Watts Guerra LLC & 12 Other Firms Representing Vast Majority of Johnson & Johnson Talc Claimants, Announce Broad Support for New \$8.9 Billion Settlement with J&J”		
PI 2 Exhibit 56	Watts Deposition Exhibit 4 - Slides re Talc Settlement, presented April 12, 2023		
PI 2 Exhibit 57	Watts Deposition Exhibit 5 – Still shots of video presentation		
PI 2 Exhibit 58	Birchfield Deposition Exhibit 001 - 9/5/2020 Email from Birchfield to Murdica re: <b>**Confidential**</b> with attachment “TALC TERM SHEET (AN-5PM) (9-4-20).docx”		Confidential
PI 2 Exhibit 59	Birchfield Deposition Exhibit 002 – Confidential Settlement Term Sheet, dated 9/4/2020 5:20 PM		Confidential
PI 2 Exhibit 60	Birchfield Deposition Exhibit 004 – PowerPoint entitled, “Value of Ovarian Cancer Claims”		Confidential
PI 2 Exhibit 61	Birchfield Deposition Exhibit 005 – Beasley Allen webpage entitled, “Talcum Powder Verdicts”		
PI 2 Exhibit 62	Birchfield Deposition Exhibit 006 – Beasley Allen webpage entitled, “Talcum Powder”		
PI 2 Exhibit 63	Birchfield Deposition Exhibit 007 – Results NeoTYPE Analysis Discovery Profile for Debra Henry, dated 5/4/2020		Confidential
PI 2 Exhibit 64	Birchfield Deposition Exhibit 008 – Medical Report of Susan Vogeler, dated 4/24/2018		Confidential

Ex.	Description	Beg. Bates No.	Confidential Designation
PI 2 Exhibit 65	Birchfield Deposition Exhibit 009 – National Cancer Institute webpage entitled, “Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Prevention (PDQ) – Health Professional Version”		
PI 2 Exhibit 66	My Cancer Genome, Malignant Mesothelioma webpage		
PI 2 Exhibit 67	Excerpts from 8/20/2020 Sylvester Reyes Deposition Transcript		
PI 2 Exhibit 68	Molton Deposition Exhibit 0001 – Email chain between Greg Gordon and David Molton re: LTL		Confidential
PI 2 Exhibit 69	Watts Deposition Exhibit 6 – Email from Watts to Murdica and Itkin re: RSA-Talc with an attachment entitled, “RESTRUCTURING SUPPORT AGREEMENT-LTL (20230226-MCW).docx”		Confidential

Dated: June 26, 2023

**WOLLMUTH MAHER & DEUTSCH LLP**

/s/ Paul R. DeFilippo

Paul R. DeFilippo, Esq.

James N. Lawlor, Esq.

Joseph F. Pacelli, Esq. (admitted *pro hac vice*)

500 Fifth Avenue

New York, New York 10110

Telephone: (212) 382-3300

Facsimile: (212) 382-0050

pdefilippo@wmd-law.com

jlawlor@wmd-law.com

jpacelli@wmd-law.com

**JONES DAY**

Gregory M. Gordon, Esq.

Dan B. Prieto, Esq.

Amanda Rush, Esq.

2727 N. Harwood Street

Dallas, Texas 75201

Telephone: (214) 220-3939

gmgordon@jonesday.com

dbprieto@jonesday.com

asrush@jonesday.com

(Admitted *pro hac vice*)

*ATTORNEYS FOR DEBTOR*